Document:

EX-10.2

 Exhibit 10.2 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions. 
 GPEx® CELL LINE SALE AGREEMENT

 This GPEx® Cell Line Sale Agreement (“Agreement”) is made and is effective as of this 1st day of January, 2009
(the “Effective Date”), by and between Catalent Pharma Solutions, LLC, a Delaware limited liability company, having a place of business at 8137 Forsythia Street, Middleton, Wisconsin 53562 USA (“Catalent”), and
Moksha8 Pharmaceuticals, Inc., a Delaware corporation, having a place of business at 1550 Liberty Ridge Drive, Wayne, PA 19087, USA (“Moksha8”). 

WHEREAS, Catalent has developed and owns certain proprietary technology enabling the engineering of mammalian cell lines for the expression of
recombinant proteins (the “Technology,” as further defined below); 
 WHEREAS, Catalent will, pursuant to that certain Development
and Manufacturing Agreement dated July 14, 2008 (“DMA”) and the associated Statement of Work referred to as [***], develop for Moksha8, through the application of the Technology, a cell line (the “GPEx® Cell Line,” and including any cell lines derived in whole or part therefrom) expressing the specific Gene Expression Product (as defined below); and 

WHEREAS, Moksha8 wishes to purchase, and Catalent is willing to sell, the GPEx® Cell Line on
the terms and conditions set forth below. 
 NOW, THEREFORE, for and in consideration of the mutual covenants, conditions and undertakings
hereinafter set forth, it is agreed by and among the parties, as follows: 
  

	1.	DEFINITIONS 

 1.1 “Affiliate” means, with respect to any third party, any
corporation, firm, partnership or other entity that controls, is controlled by or is under common control with such entity; with respect to Moksha8, any corporation, firm, partnership or other entity that controls, is controlled by or is under
common control with such entity, [***] or any [***]; and with respect to Catalent, [***] and any corporation, firm, partnership or other entity [***] For purposes of this definition, “control” shall mean the ownership of at least
50% of the voting share capital of an entity or any other comparable equity or ownership interest. 
 1.2 “[***] Patent” means [***],
issued to [***], any divisionals, reissues, continuations and continuations-in-part thereof, and any foreign equivalents of the foregoing. 
 1.3
“Combination Product” means any product containing an agent or ingredient which constitutes at least one Product and one or more other active agents or ingredients which do not by themselves constitute Products and/or one or more
other active agents, toxins, radioisotopes, or other active ingredients which do not by themselves constitute Products, whether such active agents, toxins, radioisotopes and other active ingredients are packaged separately but sold together or are
both packaged and sold together. 
 1.4 “Effective Date” means the date first above written. 

 1.5 “Gene Expression Product” means [***] Exhibit A and [***], and including, without
limitation, the gene expression products [***]. 
 1.6 “GPEx® Cell Line” has the
meaning set forth in the recitals of this Agreement. 
 1.7 “Net Sales” means, with respect to each quarterly reporting period, the [***]
for the Products covered by the Commercial License sold by or for Moksha8 (or its permitted transferees) to independent third parties in arm’s-length transactions during such quarter, after deduction [***] of the following items paid, allowed
or incurred by Moksha8, its Affiliate or its sublicensee with respect to sales of Products, provided and to the extent that such items do not exceed reasonable and customary amounts in the market in which such sales occurred: 

(a) trade, quantity and/or cash discounts, allowances or rebates actually taken and allowed, including promotional or similar discounts or
rebates and discounts or rebates to governmental or managed care organizations; 
 (b) credits, reserves or allowances given or made with
respect to Products by reason of rejection, defects, recalls, returns, rebates and retroactive price reductions; 
 (c) any tax, tariff,
duty or government charge (including any sales, value added, excise or similar tax or government charge, but excluding any income tax) levied on the sale, transportation or delivery of a Product and borne by the seller thereof without reimbursement
from any third party; 
 (d) any charges for freight, postage, shipping or transportation, or for insurance, in each case to the extent
borne by the seller; and 
 (e) any bad debt losses or reserves for bad debt losses for such quarter. 

All of the foregoing deductions [***] of Products shall be determined in accordance with GAAP. In the event that Moksha8 makes [***] pursuant to this
Agreement, the [***] shall be [***] in the [***] of any [***]. In the case of a Combination Product for which each agent or ingredient constituting a Product and each of the other active agents or active ingredients not constituting Products have
established market prices when sold separately, Net Sales shall be determined by multiplying the Net Sales for each such Combination Product by a fraction, the numerator of which shall be the established market price for the Products contained in
the Combination Product and the denominator of which shall be the sum of the established market prices for the Products plus the other active agents or active ingredients contained in the Combination Product. When such separate market prices are not
established, then the parties shall negotiate in good faith to determine a fair and equitable method of calculating Net Sales for the Combination Product in question. For the purposes of the foregoing, “Combination Product” shall have the
meaning as described in Section 1.3. Notwithstanding the foregoing, in no event shall the [***] used for [***] on a [***] than the [***] for a Product [***], for [***] in [***]. 

1.8 “Patent Rights” means rights to [***], and, as applicable, rights to [***]; and continuing applications of all the foregoing, including
divisions, substitutions and continuation-in-part applications (but only to the extent that those continuation-in-part applications are enabled by the parent application); and any patents issuing on said applications including reissues,
reexaminations and extensions; and any corresponding foreign applications or patents. 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 1.9 “Product” means any finished product that contains a Gene Expression Product, whose
manufacture utilized the GPEx® Cell Line. 
 1.10 “Sale” means any transfer to any
party other than Moksha8, its Affiliate or sublicensee, of Products for consideration. The term “First Commercial Sale” denotes the first occurrence of any such Sale of a Product in a particular country. 

1.11 “Technology” means Catalent’s proprietary technology useful in the creation and use of (i) [***] product(s) when[***] in a
[***], (ii) [***] for [***] said [***] and (iii) [***] with said [***] so that said [***], including the Patent Rights and all know-how. 
 1.12
“Territory” means all countries in the world. 
 Capitalized terms used in this Agreement but not defined herein shall have the meanings
ascribed to such terms in the DMA. 
  

	2.	SALE OF GPEX® CELL LINE 

 2.1
Evaluation Period. 
 A. Moksha8 shall have [***] from the date of delivery of the GPEx® Cell Line pursuant to Section 2.4
(the “Evaluation Period”) to evaluate the GPEX® Cell Line. The scope of evaluation activities shall be limited to growth of the GPEx® Cell Line by [***], with a place of business at [***]. Moksha8 shall not, and Moksha8
shall procure [***] written agreement not to, transfer the GPEx® Cell Line to any location other than the above-mentioned address or to any other third party under any circumstances without the express permission of Catalent. Moksha8 shall not,
and shall procure [***] written agreement not to, conduct or permit any other party to conduct on its behalf any cGMP activities in connection with the GPEx® Cell Line during the Evaluation Period. 

B. On or before the expiration date of the Evaluation Period, Moksha8 shall determine and advise Catalent in writing whether it desires to
take ownership of the GPEx® Cell Line. If Moksha8 so desires to take ownership, Section 2.2 shall apply. If Moksha8 does not desire to take ownership, it shall, on or prior to the expiration date of the Evaluation Period, cease all use of
the GPEx® Cell Line and destroy or have destroyed all quantities in its or [***] possession or control (and certify, and have [***] certify, in writing as to such destruction) and either (i) instruct Catalent to destroy all remaining
quantities of GPEx® Cell Line, in which event this Agreement shall terminate automatically without further action by either party, (ii) instruct Catalent to store all remaining quantities of GPEx® Cell Line, in which case [***] or
(iii) enter into one or more additional Statements of Work under the DMA for further work in respect of the GPEx® Cell Line. 
 C.
If Moksha8 fails to timely notify Catalent upon expiration of the Evaluation Period pursuant to Section 2.1(B) whether or not it desires to take ownership of the GPEx® Cell 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
Line, it shall be deemed, solely as an accommodation to Moksha8, that Moksha8 has notified Catalent that it does not desire to take ownership and that it has instructed Catalent to store
all remaining quantities of GPEx® Cell Line pursuant to Section 2.1(B)(ii). Catalent shall confirm its intent to store such quantities in writing to Moksha8 and will concurrently [***]. Moksha8 shall [***] in accordance with Section [***];
provided, that if Moksha8 does not [***] shall not be deemed a breach of this Agreement but instead shall be deemed notice to Catalent by Moksha8 that Moksha8 does not desire Catalent to store such remaining quantities of GPEx® Cell Line,
in which event Catalent shall be entitled to destroy all such remaining quantities of GPEx® Cell Line and this Agreement shall terminate automatically without further action by either party. 

D. In the case that Moksha8 does not desire to take ownership of the GPEx® Cell Line and timely notifies Catalent of its selection of
either the option set forth in Section 2.1(b)(ii) (including as deemed to have been selected by operation of Section 2.1(C) and Moksha8’s [***]) or in Section 2.1(B)(iii), then Moksha8 shall have the right at any time following
the expiration of the Evaluation Period — so long as Moksha8 is either [***] pursuant to Section 2.1(B)(ii) or Section 2.1(C) or has Catalent engaged in the active conduct of, and is paying for, further work pursuant to
Section 2.1(B)(iii) (such additional period, the “Option Period”) — to notify Catalent in writing that it desires to take ownership of the GPEx® Cell Line, in which case Section 2.2 shall apply. For the avoidance
of doubt, Moksha8 shall have no right to possess or use in any way the GPEx® Cell Line during the Option Period (unless and until appropriate notice of Moksha8’s desire to initiate ownership under Section 2.2 is given). For further
avoidance of doubt, the Option Period shall not be deemed to expire in connection with any failure by Moksha8 to [***] referred to in this Section 2.1(D) until any applicable procedures with respect to notification and cure of such [***]
(whether available pursuant to this Agreement or any other agreement between the parties applicable to such storage or work) shall have been followed. 

E. If Moksha8 fails to notify Catalent within [***] following the expiration of the Option Period pursuant to Section 2.1(D) that it
desires to take ownership of the GPEx® Cell Line, it shall be deemed that Moksha8 has notified Catalent that it does not desire to take ownership, in which event Catalent shall be entitled to destroy all remaining quantities of GPEx®
Cell Line and this Agreement shall terminate automatically without further action by either party; provided, that prior to such destruction, Catalent shall provide Moksha8 with written notice of its intent to so destroy such quantities and a
[***] grace period in which Moksha8 can notify Catalent in writing of its desire to take ownership of the GPEx® Cell Line, in which case Section 2.2 shall apply. If no such notice is received from Moksha8 within such [***] grace period,
Catalent shall be entitled to proceed with destruction. 
 2.2 Sale. Following receipt by Catalent of Moksha8’s desire to take ownership of the
GPEx® Cell Line in accordance with Section 2.1(B) (the “Purchase Notice”) and of the fee described in Section 3.1(A)(ii), Catalent shall, and does, sell and transfer to Moksha8 all rights and title to the GPEx® Cell Line; provided that Moksha8 shall use the GPEx® Cell Line solely for developing, testing, seeking regulatory approvals (including an IND or equivalent non-US filings) for, marketing and
otherwise commercially exploiting Product(s). Such sale is and shall remain contingent upon the continued observance by Moksha8 of the terms of this Agreement, including, without limitation, the terms of this Article 2. and Article 3 below. 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 2.3 No License. The sale of the GPEx Cell Line to Moksha8 shall not be construed as a license or as
permission to (i) independently make or utilize the Technology or (ii) modify (or derive portions of) the GPEx® Cell Line for the development of products other than the Product.
Catalent acknowledges and agree that no license to any of Catalent’s intellectual property, including but not limited to its Patent Rights or Technology, is required in order for Moksha8 to use the GPEx® Cell Line to manufacture any
Products, and accordingly, Catalent hereby agrees that it shall not commence or maintain any claim, demand, suit or other action against Moksha8 alleging any infringement, misappropriation or other violation of Catalent’s intellectual property
rights, including its Patent Rights or Technology, [***]; provided, that nothing in this sentence constitutes a release. Such covenant not to sue shall be binding on any assignees or successors-in-interest to Catalent’s business. 

2.4 Delivery. Catalent shall make the GPEx® Cell Line available to Client [***], as follows: within [***] following the later of (i) payment by
Client to Catalent of the fee described in Section 3.1(A)(i) and (ii) the documentation from [***] described in Section 3.4, Catalent shall tender [***] vials of working cell bank of the GPEx® Cell Line to Client’s designated
common carrier. Title to and risk in the GPEx® Cell Line shall pass to Client [***]. Catalent shall retain the remainder of the GPEx® Cell Line for the duration of the Evaluation Period at no additional charge to Moksha8. Following
expiration of the Evaluation Period, if Moksha8 elects to take ownership of the GPEx® Cell Line pursuant to Section 2.2, Moksha8 may have all or a portion of the remainder of the GPEx® Cell Line (including the associated master cell
bank) shipped to the location of its choice [***]. The parties shall cooperate to determine the details of such shipping and/or storage as and when appropriate. and/or 

2.5 Use. Moksha8 shall comply with all applicable laws and regulations, and with all published governmental guidelines, pertaining to the use,
handling, storage, transportation, disposition, and containment of said GPEx® Cell Line and all Products. 
  

	3.	PAYMENTS FOR PURCHASE 

 3.1 Payments. Moksha8 agrees to make the following payments in
consideration for the sale of the GPEx® Cell Line: 
 A. Moksha8 shall pay Catalent
milestone fees on the following schedule, which fees shall be non-refundable and non-creditable: 
 (i) $[***] within [***]
of the Effective Date; 
 (ii) $[***] within [***] of delivery of the Purchase Notice; 

(iii) $[***] upon the [***] (a) [***] (defined as the [***]) with respect to [***]; (b) [***] for the [***], and
(c) [***] (defined as the [***]) of a [***] for the [***]; 
 (iv) $[***] upon [***] (defined as the [***]) of the [***]
for the [***]; and 
 (v) $[***] upon [***] of a [***] for the [***]. 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 Moksha8 shall notify Catalent of the achievement of each milestone described in clauses (iii), (iv) and
(v) within [***] following its achievement. 
 B. Moksha8 shall pay Catalent, on a calendar quarterly basis, a contingent sale fee
equal to [***]% of Net Sales for each Product as long as the GPEx® Cell Line is used to manufacture such Product. This contingent sale fee shall be reduced by [***]% (to a final contingent sale fee equal to [***]%) on the date that is 20 years
after first commercial sale of such Product. 
 3.2 Payment Terms. Payments shall be paid in United States dollars at Catalent’s principal place
of business or such other place as Catalent may reasonably designate: (i) for the milestone payments described in Sections 3.1(A)(i) and (ii), as set forth therein; (ii) for the milestone payments described in Sections 3.1(A)(iii),
(iv) and (v), within [***] following the later of (x) achievement of each of the above milestones or (y) receipt by Moksha8 of a written invoice for such milestone payment; (ii) for contingent fee payments on Net Sales, within
[***] following the conclusion of each calendar quarterly period (i.e., ending March 31, June 30, September 30 and December 31); and (iii) for [***] following receipt by Moksha8 of a written invoice. If any
conversion of foreign currency to U.S. dollars shall be required in connection with the payments hereunder, such conversion shall be made at the exchange rate for the relevant currency [***] on the last business day of the quarterly reporting period
to which any such payment relates. 
 3.3 Further Transfer. Moksha8 shall have the right to sell, sublicense or otherwise transfer its rights to the
GPEx® Cell Line to third parties, provided that (i) Moksha8 provides written notice to Catalent of such proposed sale, sublicense or transfer at least [***] and (ii) such third party
agrees in a writing reasonably acceptable to Catalent to assume Moksha8’s obligations under this Agreement, including obligations to make all relevant payments due to Catalent under this Agreement. Notwithstanding any such subsequent sale,
sublicense or transfer, unless otherwise agreed in writing by Catalent, Moksha8 shall remain obligated with respect to all payments becoming due and payable under this Article 3 following the date of any such sale, sublicense or transfer. 

3.4 Transfer to CMO. Moksha8 shall have the right to transfer the GPEx® Cell Line to a third
party contract manufacturer provided that such party agrees in advance in a writing reasonably acceptable to Catalent not to transfer the GPEx® Cell Line or any Product to any party other than
Moksha8 or Moksha8’s designated recipients (e.g., its Affiliate or sublicensees). [***] will provide such documentation to Catalent prior to transfer of the GPEx® Cell Line for the Evaluation Period. 

3.5 Technology Transfer. In connection with the first transfer of the GPEx® Cell Line to [***] pursuant to Section 2.1, Catalent shall
cooperate with Moksha8 and [***] to ensure a quick technology transfer sufficient to enable [***] to use the GPEx® Cell Line for the evaluation activities permitted by Section 2.1. To
this end, Catalent’s obligations shall be solely as follows, unless otherwise agreed in advance by the parties: (i) to ship to [***] at the address described in Section 2.1 the GPEx® Cell Line as described in Section 2.4,
(ii) to deliver to [***] copies of all batch production records (if applicable) and project reports relating to such GPEx® Cell Line, and (iii) to afford [***] reasonable access (via telephone conference or at Catalent’s Middleton
facility) to Catalent’s scientists involved in the creation and other services associated with such 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
GPEx® Cell Line [***]. Moksha8 agrees to compensate Catalent at the rate of $[***] per man hour for each hour exceeding [***] man hours, and to [***] associated with Catalent’s
technology transfer services. Except as set forth above, Catalent shall not receive any additional compensation for such technology transfer. In the event Moksha8 desires technology transfer assistance in excess of the foregoing, the parties shall
negotiate in good faith the scope and fees for such assistance. 
  

	4.	REPORTS AND RECORDS 

 4.1 Maintenance. Moksha8 shall keep full, true, and accurate books
and records, which shall contain all information that may be necessary for the purpose of demonstrating Moksha8’s compliance with the payment obligations under this Agreement. Said books of account shall be kept at Moksha8’s principal
place of business. Moksha8 shall retain such records for no less than [***] after the close of any such calendar year. 
 4.2 Inspection. Said books
and the supporting data shall be open to inspection on behalf of Catalent upon no less than [***] written notice during normal business hours to the extent necessary to verify Moksha8’s payment statements or compliance in other respects with
the payment obligations under this Agreement. Such inspection shall be made not more often than once each calendar year at the expense of Catalent by a Certified Public Accountant [***]; provided, that if such inspection results in an adjustment of
[***] percent ([***]%) or greater in favor of Catalent in the overall payment due for the period being audited, then Moksha8 shall reimburse Catalent for its reasonable costs incurred in performing such inspection. 

4.3 Reports. Moksha8, commencing upon the close of the first calendar quarter following the date of the First Commercial Sale of a Product, shall
deliver to Catalent, no later than [***] following the close of each calendar quarter, true and accurate reports setting forth the Net Sales during such quarterly period and the contingent fee payment due for such quarter. Such reports shall include
a detailed calculation of Net Sales for such quarterly period, including, without limitation, the following information: 
 (a) Gross sales
of Product on a country-by-country basis; 
 (b) Permitted adjustments to gross sales required to calculate Net Sales; 

(c) Calculation of the contingent fee payment due hereunder for such quarterly period; and 

(d) [***]. 
 In the event that no Product sales
are made during any such quarterly period, Moksha8 shall so inform Catalent in writing within the time period for otherwise providing the report anticipated hereby. 

4.4 Interest. Any undisputed payments due from Moksha8 that are not paid on the date such payments are due under this Agreement shall bear interest at
[***], with the [***]. 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

	5.	TERM AND TERMINATION 

 5.1 Term. This Agreement shall be in full force and effect from the
Effective Date and shall remain in effect unless and until terminated in accordance with the provisions of this Article 5. 
 5.2 Termination by
Client. Moksha8 shall have the right to terminate this Agreement without cause by giving notice in writing to Catalent at least thirty (30) days in advance of the termination date. 

5.3 Mutual Termination Rights. Either party shall have the right (but not the obligation) to immediately terminate this Agreement on written notice if
(a) the other party files a petition in bankruptcy, or enters into an agreement with its creditors, or applies for or consents to the appointment of a receiver or trustee, or makes an assignment for the benefit of creditors, or suffers or
permits the entry of any order adjudicating it to be bankrupt or insolvent and such order is not discharged within thirty (30) days; or (b) if the other party materially breaches this Agreement, and such material breach is not cured within
sixty (60) days after such other party receives written notice specifying the breach and demanding its cure. 
 5.4 Automatic Termination. This
Agreement shall terminate automatically in accordance with Sections 2.1(B), (C) and (E). 
 5.5 Effects of Termination. 

A. Upon termination pursuant to Section 5.2 or 5.3 (except for termination because of Catalent’s breach of this Agreement),
Moksha8’s ownership rights in the GPEx® Cell Line shall automatically terminate and title thereto shall revert to Catalent; provided, however, that at Moksha8’s option each of the
parties shall promptly destroy (and certify to the other party that it has destroyed) all remaining stores of the GPEx® Cell Line (including any cells or cell lines derived therefrom) in its
possession, except that each party may retain a reasonable legacy quantity of the GPEx® Cell Line solely for archival uses. Upon termination of this Agreement pursuant to Section 5.2 or
5.3 (except for termination because of Catalent’s breach of this Agreement), Moksha8 shall have a period of [***] to sell any remaining inventories of Product(s) subject to the terms of this Agreement, including, without limitation, the
obligations to report and make milestone and contingent fee payments set forth in Articles 2 and 3 hereof. If Moksha8 terminates this Agreement because of Catalent’s uncured breach, then Moksha8 shall continue to own the GPEx® Cell Line and shall continue to have all rights granted to Moksha8 by Catalent, including the right to transfer the GPEx® Cell Line to contract manufacturers and all other rights set forth in
Sections 3.3 and 3.4, all without any further payment or reporting obligations to Catalent. 
 B. Upon termination of this Agreement
pursuant to Section 5.4, Moksha8’s rights to use the GPEx® Cell Line (if any) shall automatically terminate and title thereto shall remain with Catalent; provided, however, both
parties shall promptly destroy (and certify to the other party that it has destroyed) all remaining stores of the GPEx® Cell Line (including any cells or cell lines derived therefrom) in its
possession or control (including, in the case of Moksha8, in [***] possession or control). 
 C. Any termination of this Agreement shall not
relieve either party of any obligation or liability accrued hereunder prior to such termination nor shall it affect in any manner any rights of either party arising under this Agreement prior to such termination. 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 5.6 Survival. Upon the termination of this Agreement, each provision of this Agreement which, by its
nature is intended to survive the termination or expiration of this Agreement, shall continue in force and effect. Without limiting the foregoing, the following sections shall survive termination or expiration of this Agreement: Articles 2 (Sale of
GPEx® Cell Line), 5 (Term and Termination), 8 (Publicity), 9 (Patent Protection and Infringement), 10 (Confidentiality), 11 (Indemnification), 12 (Limitations on Liability), 13 (Insurance), 14 (Notice) and 15 (Miscellaneous). 

 

	6.	REPRESENTATIONS AND WARRANTIES 

 6.1 Catalent. Catalent represents and warrants to Moksha8
that (i) it has all necessary ownership or use rights to the Technology for the purpose of fulfilling its obligations under this Agreement, (ii) it has the lawful right to sell the
GPEx® Cell Line pursuant to this Agreement and (iii) [***] Moksha8’s use of the GPEx® Cell Line in accordance with this Agreement will not infringe any patent, copyright, trade
secret or other intellectual property rights of any third party. 
 OTHER THAN THE FOREGOING, CATALENT MAKES NO (AND HEREBY DISCLAIMS ANY) EXPRESS OR
IMPLIED WARRANTIES WITH RESPECT TO THE GPEX CELL LINE OR THE PRODUCTS, INCLUDING, WITHOUT LIMITATION, ANY WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. 

6.2 Moksha8. Moksha8 represents and warrants to Catalent that (i) it has provided, and will provide during the term of this Agreement, [***]
applicable to [***] and to and any [***]; (ii) the GPEx® Cell Line along with all Product delivered to Moksha8 by Catalent will be held, used and/or disposed of by Moksha8 in accordance
with all applicable laws; and (iii) Moksha8 will comply with all applicable laws and regulations applicable to Moksha8’s performance under this Agreement. 

6.3 Mutual. Each party hereby represents and warrants to the other party that: 

A. Existence and Power. Such party (i) is duly organized, validly existing and in good standing under the laws of the state in
which it is organized, (ii) has the power and authority and the legal right to own and operate its property and assets, and to carry on its business as it is now being conducted, and (iii) is in compliance with all requirements of
applicable laws, except to the extent that any noncompliance would not materially adversely affect such party’s ability to perform its obligations under the Agreement; 

B. Authorization and Enforcement of Obligations. Such party (i) has the power and authority and the legal right to enter into this
Agreement and to perform its obligations hereunder and (ii) has taken all necessary action on its part to authorize the execution and delivery of this Agreement and the performance of its obligations hereunder. 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 C. Execution and Delivery. This Agreement has been duly executed and delivered on behalf
of such party, and constitutes a legal, valid, binding obligation, enforceable against such party in accordance with its terms; 
 D. No
Consents. All necessary consents, approvals and authorizations of all Regulatory Authorities and other persons required to be obtained by such party in connection with the execution, delivery and performance of this Agreement have been obtained;
and 
 E. No Conflict. The execution and delivery of this Agreement and the performance of such party’s obligations hereunder
(i) do not conflict with or violate any requirement of applicable laws; and (ii) do not materially conflict with, or constitute a material default or require any consent under, any contractual obligation of such party. 

 

	7.	GOVERNMENT COMPLIANCE  

 7.1 Government Approvals. The manufacture, transfer, sale and/or
export of the GPEx® Cell Line or Product(s) may require a license or approval from an agency of the United States government. Moksha8 shall be solely responsible for obtaining all licenses,
permits, or authorizations required from the United States and any other government for any use or sale of the GPEx® Cell Line and/or Product(s). To the extent not inconsistent with this
Agreement, Catalent agrees to provide Moksha8 (at Moksha8’s expense) with such assistance as Moksha8 may reasonably request in filing for, seeking and/or obtaining such licenses, permits, or authorizations. Such services shall be provided in
accordance with the terms set forth in a separate service agreement to be agreed upon by the parties. 
 7.2 Cooperation. Moksha8 and Catalent agree
to cooperate in making required submissions to the U.S. Food and Drug Administration (FDA) and/or other regulatory agencies. Catalent expressly agrees that Moksha8 shall have the right to reference any and all Drug Master Files relating to any
Product or Technology covered by this Agreement insofar as such information is necessary or desirable in the prosecution of any submission to the FDA and/or other regulatory agencies. 

 

	8.	PUBLICITY 

 8.1 Names. Neither party shall use the name of the other party or inventors of
the Technology in any advertising, promotion, or sales without the prior written consent of the other party in each case, except that Moksha8 may state that the Products have been manufactured utilizing a GPEx® Cell Line produced under one or more of the patent and applications comprising Catalent’s Patent Rights; provided, however, that each party may use the other party’s name without such
prior written consent to the extent that such use is required by any applicable law, rule or regulation now in effect or promulgated hereafter. 
 8.2
Generic Data. Moksha8 agrees to allow Catalent to use data obtained from development of the Product, provided such data does not identify Moksha8, the GPEx® Cell Line or any Product,
for marketing and demonstration of the Technology to third parties. 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 8.3 Public Announcements. Neither Catalent nor Moksha8 will, without the prior consent of the other, such
consent not to be unreasonably withheld, issue any press release or make any other public announcement or furnish any statement to any person or entity (other than either parties’ respective Affiliates and potential partners who have signed a
confidentiality agreement with terms no less restrictive than those contained herein) concerning the existence of this Agreement, its terms and the transactions contemplated hereby, except for disclosures made in compliance with Sections 8.1 and
8.2. Further, Moksha8 may disclose the existence and general terms of the Agreement in confidence to its directors, existing investors and professional service providers and to prospective investors, collaborators, licensees, strategic alliance
partners, acquirers and/or merger partners and their respective professional advisors. 
  

	9.	PATENT PROTECTION AND INFRINGEMENT 

 9.1 Third Party Infringement. If, at any time during
the term of this Agreement, either party shall become aware of any third party infringement or threatened infringement of any of the Patent Rights relating to GPEx® Cell Line or any Product,
the following provisions shall apply: 
 A. The party becoming so aware shall forthwith give written notice to the other of such
infringement. 
 B. Catalent shall have the right to litigate such alleged third party infringement in such country. Catalent shall notify
Moksha8 within [***] after the written notice described in Clause (A) above whether it intends to so litigate. Moksha8 shall, upon request of Catalent and at Catalent’s sole expense, provide Catalent with all such assistance as it may
reasonably require in the conduct of such claims or proceedings. Catalent shall bear the cost of such proceedings and shall be entitled to [***]. 

C. If Catalent determines not to litigate in accordance with clause (B) above, then Moksha8 may, in its sole discretion and expense,
bring suit (in its name if allowed under the relevant standing rules or in Catalent’s name if Catalent is required to be a party to the litigation proceeding) to restrain such third party infringement. In such event Moksha8 shall conduct such
proceedings properly and diligently and shall keep Catalent timely apprised of the course of such litigation. Catalent shall cooperate with Moksha8 in prosecuting such litigation, and shall, if necessary, join the lawsuit as a co-plaintiff (or as
sole plaintiff if Moksha8 lacks standing as a plaintiff). The net proceeds of such action will be retained by Moksha8 [***]. 
 D. In the
event of any action permitted under this Section 8.2 by either party, the other party will provide the necessary and timely assistance in such action on reasonable terms and conditions to be agreed on at such time. In connection with any
deliberations concerning the prospects for successfully bringing suit to enjoin such infringement, the parties shall promptly and fully make available to each other their information concerning the validity and enforceability of the relevant Patents
and any other relevant information. 
 9.2 Notice of Infringement. Each party hereto shall notify the other promptly in the event of the receipt of
notice of any action, suit or claim alleging infringement by the manufacture, development, use and sale of the GPEx® Cell Line or any Product of any third party intellectual property rights.
The parties shall meet promptly to discuss an appropriate response. 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

	10.	CONFIDENTIALITY 

 10.1 Mutual Obligation. Each party agrees that it shall not disclose the
other party’s Confidential Information (defined below) to any third party, and shall not use such Confidential Information for any use or purpose except as expressly permitted in this Agreement, without the prior written consent of the other
party, except as otherwise provided in this Article 10. Notwithstanding the foregoing, a party may disclose specific Confidential Information of the other party to the extent that such disclosure is required by law, regulation or court or
administrative process or order; provided, however, that prior to making any such required disclosure, the party making such disclosure shall give the other party as much prior notice of the requirement for and contents of such disclosure as is
practicable under the circumstances, and that the party making such disclosure cooperates reasonably with any efforts of the other party to obtain a protective order, confidential treatment or other protection regarding the required disclosure.
Further, each party may disclose the other party’s Confidential Information to any of its Affiliates that (i) need to know such Confidential Information for the purpose of performing under this Agreement, (ii) are advised of the
contents of this Article 10, and (iii) agree to be bound by the terms of this Article 10. Notwithstanding the above, Moksha8 shall have the right to disclose the existence and terms and conditions of this Agreement to investors, potential
investors, joint venture partners, and potential joint venture partners, as well as to legal and financial advisors, so long as each such person or entity receiving information is bound in writing by obligations of confidentiality at least as strict
as those set forth in this Article 10 with respect to the non-disclosure and non-use of such information. 
 10.2 Definition. As used in this
Agreement, the term “Confidential Information” of a party means all information furnished by such party, or any of its representatives or Affiliates, to the other party, or to any of its representatives or Affiliates, in connection
with this Agreement, whether furnished before, on or after the date of this Agreement and furnished in any form, including written, verbal, visual, electronic or in any other media or manner. The term “Confidential Information”
includes any and all proprietary technologies, know-how, trade secrets, discoveries, inventions and any other intellectual property (whether or not patented), analyses, compilations, business or technical information and other materials prepared by
a party, or any of its representatives, containing or based in whole or in part on any such information furnished by the other party or its representatives. Confidential Information also includes the existence of this Agreement and its terms. 

10.3 Exclusions. Notwithstanding Section 10.2, the term “Confidential Information” does not include information that (i) is
or becomes generally available to the public or within the industry to which such information relates other than as a result of a breach of this Agreement by the receiving party, or (ii) is already known by the receiving party at the time of
disclosure as evidenced by the receiving party’s written records, or (iii) becomes available to the receiving party on a non-confidential basis from a source that is entitled to disclose it on a non-confidential basis, or (iv) was or
is independently developed by or for the receiving party without access to any of the Confidential Information of the other party, as evidenced by the receiving party’s written records. 

10.4 No Implied License. The receiving party obtains and will obtain no right of any kind or license under any patent application or patent of the
other party by reason of this Agreement. All Confidential Information will remain the sole property of the party disclosing such information or data. 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 10.5 Return of Confidential Information. Upon expiration or termination of this Agreement, the receiving
party shall, upon request, promptly return within [***] all Confidential Information of the other party, including any copies thereof, and cease its use or, at the request of the disclosing party, shall promptly destroy the same and certify such
destruction to the disclosing party; except for a single copy thereof, which may be retained for the sole purpose of determining the scope of the obligations incurred under this Agreement. 

10.6 Survival. The obligations of this Article 10 will terminate [***] from the expiration or termination of this Agreement, except with respect to
trade secrets, for which the obligations of this Article 10 will continue for so long as such information remains a trade secret under, applicable law. 
  

	11.	INDEMNIFICATION 

 11.1 Indemnification by Catalent. Catalent shall indemnify and hold
harmless Moksha8, its Affiliates, and their respective directors, officers, employees and agents (“Moksha8 Indemnitees”) from and against any and all suits, claims, losses, demands, liabilities, damages, costs and expenses
(including reasonable attorneys’ fees) (“Losses”) arising out of or in connection with any proceeding, suit, demand or action by any third party (“Third Party Claim”) arising out of or resulting from
(i) any breach by Catalent (or its Affiliate) of its representations, warranties or obligations set forth in this Agreement or (ii) any [***] willful misconduct by Catalent; except to the extent that any such Losses arise out of or result
from any Moksha8 Indemnitee’s negligence, willful misconduct or breach of this Agreement. 
 11.2 Indemnification by Moksha8. Moksha8 shall
indemnify and hold harmless Catalent, its Affiliates, and their respective directors, officers, employees and agents (“Catalent Indemnitees”) from and against all Losses arising out of or in connection with any Third Party Claim
arising out of or resulting from (i) any breach of Moksha8’s representations, warranties or obligations set forth in this Agreement; (ii) any [***] or any of [***], any of [***] of any of the foregoing; (iii) any [***] to the
[***] or any of [***], any of [***] of any of the foregoing, including any [***] or [***]; (iv) the conduct of any clinical trials relating to any Product; (v) any actual or alleged infringement, misappropriation or violation of any third
party’s patent, trade secret, copyright, trademark or other proprietary rights arising from use of any intellectual property provided by Moksha8; or (vi) any negligence or willful misconduct by Moksha8; except to the extent that any such
Losses arise out of or result from any Catalent Indemnitee’s negligence, willful misconduct or breach of this Agreement. 
 11.3 [***]. [***],
or any other provision of this Agreement, [***] in respect of any [***]. 
 11.4 Indemnification Procedures. All indemnification obligations in this
Agreement are conditioned upon the party seeking indemnification: (i) promptly notifying the indemnifying party of any claim or liability of which the party seeking indemnification becomes aware (including a copy of any related complaint,
summons, notice or other instrument); provided, however, that failure to provide such notice within a reasonable period of time shall not relieve 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
the indemnifying party of any of its obligations hereunder except to the extent the indemnifying party is prejudiced by such failure; (ii) cooperating with the indemnifying party in the
defense of any such claim or liability (at the indemnifying party’s expense); and (iii) not compromising or settling any claim or liability without prior written consent of the indemnifying party. 

 

	12.	LIMITATIONS OF LIABILITY 

 12.1 EXCEPT WITH RESPECT TO LOSSES OWING TO CLIENT UNDER SECTION 11.1
WITH RESPECT TO AMOUNTS PAID BY CLIENT TO THIRD PARTIES FOR BODILY INJURY (IN WHICH CASE THE FOLLOWING LIMITATION SHALL NOT APPLY), [***] TOTAL LIABILITY, WHETHER IN CONTRACT OR TORT, INCLUDING ANY OF [***] INDEMNITY OR OTHER FINANCIAL OBLIGATIONS
UNDER ARTICLE 11, SHALL [***]. 
 12.2 NEITHER PARTY SHALL BE LIABLE TO THE OTHER PARTY FOR INDIRECT, INCIDENTAL, SPECIAL OR CONSEQUENTIAL DAMAGES ARISING
OUT OF PERFORMANCE UNDER THIS AGREEMENT, INCLUDING LOSS OF REVENUES, PROFITS OR DATA, WHETHER IN CONTRACT OR TORT, EVEN IF SUCH PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES. 

 

	13.	INSURANCE  

 13.1 Catalent 

A. During the term of this Agreement, Catalent shall obtain and maintain the following insurance with limits not less than those specified
below: 
  

	 	(i)	Commercial General Liability insurance with a limit of not less than [***] Dollars ($[***]) per occurrence. 

  

	 	(ii)	Products and Completed Operations Liability insurance with a limit of not less than [***] Dollars ($[***]) per occurrence. 

  

	 	(iii)	Worker’s Compensation and Employers Liability Insurance with statutory limits for Workers’ Compensation and Employers’ Liability limits of not less than [***] Dollars ($[***]) per accident.

  

	 	(iv)	Professional Services Liability insurance with a limit of not less than [***] Dollar ($[***]) per claim. 

B. Catalent may self-insure any or a portion of the required insurance. In the event that any of the required policies of insurance are
written on a claims made basis, then such policies shall be maintained during the entire term of this Agreement and for a period of not less than [***] following the termination or expiration of this Agreement. 

C. Catalent shall waive subrogation rights against Moksha8 for workers’ compensation benefits and shall obtain a waiver from any
insurance carriers with which Catalent carries workers’ compensation insurance releasing their subrogation rights against Moksha8. Catalent shall not seek reimbursement for any property claim, or portion thereof, which is not fully recovered
from Catalent’s Property insurance. 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 D. Moksha8 and its Affiliates shall be [***] under the Commercial General Liability and Products
and Completed Operations Liability insurance policies with respect to [***] provided under this Agreement. Such [***] shall end upon the termination or expiration of this Agreement unless the policies are written on a claims made basis when such
[***] will continue for the period of time Catalent is required to [***]. 
 E. Catalent shall furnish certificates of insurance to Moksha8
evidencing the required insurance [***] as soon as practicable after the Effective Date and within [***] after renewal of such policies. Such certificates shall state that Catalent’s insurers will endeavor to provide [***] written notice of any
cancellation prior to the policy(ies) expiration date(s). Each insurance policy that is required under this Section shall be obtained from an insurance carrier with [***]. 

13.2 Client. 
 A. During the term of this
Agreement, Client shall obtain and maintain the following insurance with limits not less than those specified below. 
  

	 	(i)	Commercial General Liability insurance with a limit of not less than [***] Dollars ($[***]) per occurrence. 

  

	 	(ii)	Products and Completed Operations Liability insurance with a limit of not less than [***] Dollars ($[***]) per occurrence (to be maintained only immediately prior to and during use of Drug Substance or Drug Product in
humans). 

  

	 	(iii)	Worker’s Compensation and Employers Liability Insurance with statutory limits for Workers’ Compensation and Employers’ Liability limits of not less than [***] Dollars ($[***]) per accident.

  

	 	(iv)	All Risk Property Insurance, including transit coverage, in an amount equal to [***] while it is [***] or in [***]. 

B. Moksha8 may self-insure any or a portion of the required insurance. In the event that any of the required policies of insurance are written
on a claims made basis, then such policy(ies) shall be maintained during the entire period of this Agreement and for a period of not less than [***] following the termination or expiration of this Agreement. 

C. Moksha8 shall waive subrogation rights against Catalent for workers’ compensation benefits and shall obtain a waiver from any
insurance carriers with which Moksha8 carries workers’ compensation insurance releasing their subrogation rights against Catalent. Moksha8 shall not seek reimbursement for any property claim, or portion thereof, which is not fully recovered
from Moksha8’s Property insurance. 
 D. Catalent Inc. and Affiliates shall be [***] under the Commercial General Liability and
Products and Completed Operations Liability insurance policies with respect to [***] provided under this Agreement. Moksha8’s Commercial General Liability and Products and Completed Operation Liability policies shall provide that [***] (with
respect both to [***] and to [***]) with regard to [***] arising out of [***] for which [***]. Such [***] shall end upon the termination or expiration of this Agreement unless the policies are written on a claims-made basis when [***] will continue
for the period of time Client is required to [***]. 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 E. Moksha8 shall furnish certificates of insurance to Catalent evidencing the required insurance
[***] as soon as practicable after the Effective Date and within [***] after renewal of such policies. Such certificates shall state that Moksha8’s insurers will endeavor to provide [***] written notice of any cancellation prior to the
policy(ies) expiration date(s). Each insurance policy which is required under this Section shall be obtained from an insurance carrier with [***]. 
  

	14.	NOTICES 

 All notices and other communications hereunder shall be in writing and shall be deemed
given: (a) when delivered personally; (b) when delivered by facsimile transmission (receipt verified); (c) when received or refused, if mailed by registered or certified mail (return receipt requested), postage prepaid; or
(d) when delivered if sent by express courier service, to the parties at the following addresses (or at such other address for a party as shall be specified by like notice; provided, that notices of a change of address shall be effective only
upon receipt thereof): 
  

			
	To Client:	  	moksha8 Pharmaceuticals, Inc.
		  	1550 Liberty Ridge Drive
		  	Wayne, PA 19087
		  	Facsimile: [***]
		  	Attn: [***]
		
	With a copy to:	  	moksha8 Pharmaceuticals, Inc.
		  	1550 Liberty Ridge Drive
		  	Wayne, PA 19087
		  	Facsimile: [***]
		  	Attn: Vice President, Legal
		
	To Catalent:	  	Catalent Pharma Solutions, LLC
		  	8137 Forsythia Street
		  	Middleton, Wisconsin 53562
		  	Attention: Vice President / General Manager
		  	Facsimile: [***]
		
	With a copy to:	  	Catalent Pharma Solutions, LLC
		  	14 Schoolhouse Road
		  	Somerset, NJ 08873
		  	Attention: General Counsel (Legal Department)
		  	Facsimile: [***]

  

	15.	MISCELLANEOUS 

 15.1 Entire Agreement; Amendments. This Agreement, its attachments and any
amendments thereto, together with the DMA, constitute the entire understanding between the parties with 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
respect to the subject matter hereof and supersede any prior contracts, agreements or understanding (oral or written) of the parties as to such subject matter. No term of this Agreement may be
amended except upon written agreement of both parties. 
 15.2 Captions; Certain Conventions. The captions in this Agreement are for convenience only
and are not to be interpreted or construed as a substantive part of this Agreement. Unless otherwise expressly provided herein or the context of this Agreement otherwise requires, (i) words of any gender include each other gender;
(ii) words such as “herein,” “hereof” and “hereunder” refer to this Agreement as a whole and not merely to the particular provision in which such words appear; (iii) words using the singular shall include the
plural, and vice versa; (iv) the words “include(s)” and “including” shall be deemed to be followed by the phrase “but not limited to,” “without limitation” or words of similar import; (v) the word
“or” shall be deemed to include the word “and” (e.g. “and/or”); and (vi) references to “Article,” “Section,” “subsection,” “clause” or other subdivision, or to an Attachment
or other appendix, without reference to a document are to the specified provision or Attachment of this Agreement. 
 15.3 Further Assurances. The
parties agree to execute, acknowledge and deliver such further instruments and to take all such other incidental, reasonable acts as may be reasonably necessary or appropriate to carry out the purpose and intent of this Agreement. 

15.4 No Waiver. Failure by either party to insist upon strict compliance with any term of this Agreement in any one or more instances will not be
deemed to be a waiver of its rights to insist upon such strict compliance with respect to any subsequent failure. 
 15.5 Severability. If any term
of this Agreement is declared invalid or unenforceable by a court or other body of competent jurisdiction, the remaining terms of this Agreement will continue in full force and effect. 

15.6 Independent Contractors. The relationship of the parties is that of independent contractors, and neither party will incur any debts or make any
commitments for the other party except to the extent expressly provided in this Agreement. Nothing in this Agreement is intended to create or will be construed as creating between the parties the relationship of joint ventures, co-partners,
employer/employee or principal and agent. 
 15.7 Successors and Assigns. This Agreement will be binding upon and inure to the benefit of the
parties, their successors and permitted assigns. Neither party may assign this Agreement, in whole or in part, without the prior written consent of the other party, except that either party may, without the other party’s consent, assign this
Agreement to an Affiliate or to a successor to substantially all of the business or assets of the assigning company (or the assigning company’s business unit responsible for performance under this Agreement). Moksha8 shall be [***] of any of
[***], including those [***] pursuant to Section [***]. 
 15.8 Governing Law. This Agreement shall be governed by and construed under the laws of
the State of New Jersey, excluding its conflicts of law provisions. The United Nations Convention on Contracts for the International Sale of Goods shall not apply to this Agreement. 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 15.9 Alternative Dispute Resolution. If any Dispute arises between the parties, such Dispute shall be
presented to the respective presidents or senior executives of Catalent and Client for their consideration and resolution. If such parties cannot reach a resolution of the Dispute within [***] after such Dispute has been presented to the presidents
or senior executives, then such Dispute shall be resolved by binding arbitration in accordance with the then existing CPR Rules for Non-Administered Arbitration by three arbitrators of whom each party shall appoint one in accordance with the
‘screened’ appointment procedure provided in CPR Rule 5.4. Arbitration shall be conducted in the jurisdiction of the defendant party. The arbitration shall be governed by the Federal Arbitration Act, 9 U.S.C. §§1 et seq., and
judgment upon the award rendered by the arbitrators may be entered by any court of competent jurisdiction. 
 15.10 Prevailing Party. In any dispute
resolution proceeding between the parties in connection with this Agreement, the prevailing party will be entitled to recover its reasonable attorney’s fees and costs in such proceeding from the other party. 

15.11 Counterparts. This Agreement may be executed in one or more counterparts, each of which will be deemed an original but all of which together will
constitute one and the same instrument. Any photocopy, facsimile or electronic reproduction of the executed Agreement shall constitute an original. 
 15.12
Force Majeure. Except as to payments required under this Agreement, neither party shall be liable in damages for, nor shall this Agreement be terminable or cancelable by reason of, any delay or default in such party’s performance
hereunder if such default or delay is caused by events beyond such party’s reasonable control including, but not limited to, acts of God, regulation or law or other action or failure to act of any government or agency thereof, war or
insurrection, civil commotion, destruction of production facilities or materials by earthquake, fire, flood or storm, labor disturbances, epidemic, or failure of suppliers, public utilities or common carriers; provided however, that the party
seeking relief hereunder shall immediately notify the other party of such cause(s) beyond such party’s reasonable control. The party that may invoke this section shall use all reasonable endeavors to reinstate its ongoing obligations to the
other. If the cause(s) shall continue unabated for [***], then both parties shall meet to discuss and negotiate in good faith what modifications to this Agreement should result from this force majeure. 

[Signature page follows] 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 IN WITNESS WHEREOF, both Catalent and Moksha8 have executed this Agreement, in duplicate originals, by their
respective officers hereunto duly authorized, on the day and year hereinafter written. 
 Agreed to and accepted by: 

 

									
	Moksha8 Pharmaceuticals, Inc.	 		 	Catalent Pharma Solutions, LLC
					
	By:	 	 /s/ Simba Gill
	 		 	By:	 	 /s/ Michael Jenkins

					
	Name:	 	 Simba Gill
	 		 	Name:	 	 Michael Jenkins

					
	Title:	 	 CEO
	 		 	Title:	 	 General Manager

					
	Date:	 	 1/23/09
	 		 	Date:	 	 02/04/09

 Signature Page to GPEx® Cell Line Sale Agreement 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 Exhibit A 

[***] 
 Gene Expression Products: 

m80015 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 Execution Copy 

AMENDMENT TO GPEx® CELL LINE SALE AGREEMENT 

This amendment to the GPEx® Cell Line Sale Agreement (the “Amendment”) is made and is effective this 31st day of July, 2009 (the “Amendment Effective Date”), by and between Catalent Pharma Solutions, LLC, a Delaware limited liability company, having a place of business at 8137 Forsythia
Street, Middleton, Wisconsin 53562 USA (“Catalent”), and Fourteen22, Inc., a Cayman corporation, having its registered office at c/o M&C Corporate Services Limited, P.O. Box 309GT, Ugland House, South Church Street, George Town,
Grand Cayman, Cayman Islands (“1422”). Catalent and 1422 are referred to herein individually as a “Party” or collectively as the “Parties.” 

WHEREAS, Moksha8 Pharmaceuticals, Inc., a Delaware corporation, having a place of business at 1550 Liberty Ridge Drive, Suite 300, Wayne, P.A 19087,
USA (hereinafter referred to as “Moksha8”) and Catalent entered into the Development and Manufacturing Agreement dated July 14, 2008 (“DMA”) and the associated Statement of Work referred to as [***], pursuant
to which Catalent developed for Moksha8 a cell line expressing the Gene Expression Product designated as m80015 (the “GPEx® Cell Line”); and 

WHEREAS, Moksha8 and Catalent entered into the GPEx® Cell Line Sale Agreement dated January 1, 2009 (the “CLSA”), pursuant to
which Moksha8 has the option to purchase the rights to the GPEx® Cell Line; and 
 WHEREAS,
Moksha8 assigned its rights and delegated its obligations under the DMA and CLSA to its Affiliate, 1422; and 
 WHEREAS, the Parties desire to amend
certain payment and related terms of the CLSA; 
 NOW, THEREFORE, for good and valuable consideration, the receipt and adequacy of which are hereby
acknowledged, the Parties agree as follows: 
  

	1.	Deferral of Payments. 

 1.1. Section 3.1(A)(ii) of the CLSA is
hereby replaced in its entirety with the following: 
 “(ii) $[***] within [***] of delivery of the Purchase Notice; 

(iii) $[***] by [***];” 

1.2. Subsections (iii) through (v) of Section 3.1(A) of the CLSA are hereby renumbered (iv) through (vi), respectively,
and all cross-references thereto are hereby deemed revised accordingly (including in particular the cross-references set forth in Section 3.2(ii)). 

1.3. Sections 3.2(i) of the CLSA is hereby replaced in its entirety with the following: “(i) for the milestone payments described in
Sections 3.1(A)(i), (ii) and (iii), as set forth therein;”. 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

	2.	Effect of Non-Payment. 

 2.1. The following is hereby added to the
CLSA as a new Section 3.1(C): 
 “C. [***] in Event of Default of Certain Payments. If 1422 fails to make the payment
specified in Section 3.1(A)(iii) [as amended] when due, then (i) notwithstanding anything to the contrary in this Agreement or the DMA, the [***], (ii) 1422 shall not be relieved of its obligation to pay such amount, (iii) unless
and until such amount is paid (without prejudice to Catalent’s right to terminate this Agreement in accordance with Section 5.3), 1422 shall have no further rights to possession or use of the GPEx® Cell Line and Catalent may inform
[***] to destroy any and all GPEx® Cell Lines in its possession, and (iv) subsequent payment of such amount [***]. For the avoidance of doubt, if 1422 makes the payment specified in Section 3.1(A)(iii) when due, then 1422 shall [***]
the GPEx® Cell Line, subject to the other terms and conditions of this Agreement. The Parties acknowledge that [***] entitles (i) [***] to have the [***] and to [***] and/or [***] to [***], with or without [***] sole discretion, and [***]
shall have no right to share in any [***], and (ii) 1422 to continue to have the rights to the GPEx® Cell Line set forth in the CLSA, subject to and in accordance with its terms and conditions. If Catalent becomes [***] hereunder, then
Catalent shall have the [***] of (and [***] in its sole discretion), up to [***] and up to [***] from the [***] thereof currently held by Catalent, and shall have no [***]. 
  

	3.	Transfer of Working Cell Bank Vials. 

 3.1. Section 2.4 of the
CLSA is hereby amended by adding the following to the end of the second to last sentence: “; provided, that until the payment described in Section 3.1(A)(iii) is made, 1422 shall be [***].” 

3.2. Section 2,5 of the CLSA is hereby amended by adding the following to the end thereof: “After transfer of WCB vials pursuant to
Section 2.4, 1422 will provide the following information to Catalent on a timely basis: number of bioreactor runs carried out; expression levels obtained from such bioreactor runs; and a summary of analytical testing carried out.” 

 

	4.	Miscellaneous 

 4.1. Full Force and Effect. Except as expressly
amended hereby, the CLSA shall remain in full force and effect. 
 4.2. Governing Law. This Amendment shall be governed by and
construed under the laws of the State of New Jersey, excluding its conflicts of law provisions. 
 4.3. Entire Agreement; Further
Amendments. This Amendment, the CLSA and the DMA, including any appendices, attachments and work orders associated with such agreements, constitute the entire understanding between the Parties with respect to the subject matter hereof and
supersede any prior contracts, agreements or understanding (oral or written) of the Parties as to such subject matter. No term of this Amendment, the CLSA or the DMA may be amended except upon written agreement of both Parties. 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 4.4. Construction. 

(a) Headings are solely for the Parties’ convenience, are not a part of this Amendment, and shall not be used to interpret this
Amendment. 
 (b) The singular form shall include the plural and vice versa. 

(c) The words “include(s)” and “including” shall be deemed to be followed by the phrase “but not limited to,”
“without limitation” or words of similar import. 
 (d) The word “or” shall be deemed to include the word
“and” (e.g. “and/or”). 
 (e) This Amendment shall not be construed as if it had been prepared by one of the Parties,
but rather as if both the Parties have prepared it. 
 (f) Unless otherwise indicated, all references to sections are to sections of this
Amendment. 
 (g) Capitalized terms not otherwise defined herein shall have the meanings ascribed to them in the CLSA or the DMA. 

4.5. Severability. If any term of this Amendment is declared invalid or unenforceable by a court or other body of competent
jurisdiction, the remaining terms of this Amendment will continue in full force and effect. 
 4.6. Counterparts. This
Amendment may be executed in one or more counterparts, each of which will be deemed an original but all of which together will constitute one and the same instrument. Any photocopy, facsimile or electronic reproduction of the executed Amendment
shall constitute an original. 
 [Signature page follows] 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 IN WITNESS WHEREOF, both Catalent and 1422 have executed this Amendment, in duplicate originals, by their
respective officers hereunto duly authorized, on the day and year hereinafter written. 
 Agreed to and accepted by: 

 

									
	Fourteen22, Inc.	 		 	Catalent Pharma Solutions, LLC
					
	By:	 	 /s/ D.S. Athwal
	 		 	By:	 	 /s/ Michael Jenkins

					
	Name:	 	 D.S. Athwal
	 		 	Name:	 	 Michael Jenkins

					
	Title:	 	 Chief Scientific Officer
	 		 	Title:	 	 General Manager

					
	Date:	 	 11 Aug 2009
	 		 	Date:	 	 Aug 10, 2009

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.EX-10.3

 Exhibit 10.3 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions. 
 REVENUE AND NEGOTIATION RIGHTS AGREEMENT 

This Revenue and Negotiation Rights Agreement (the “Agreement”), dated as of December 31, 2010 (the
“Effective Date”), is entered into by and between moksha8 Pharmaceuticals, Inc. (“Moksha8”), a Delaware corporation with a mailing address of 1550 Liberty Ridge Drive, Suite 300, Wayne, PA
19087, and fourteen22, Inc. (“Fourteen22”), a Cayman Islands company with registered office at c/o Maples Corporate Services Limited, PO Box 309, Ugland House, Grand Cayman, KY1-1104, Cayman Islands. Moksha8 and
Fourteen22 shall be referred to herein individually as a “Party” and collectively as the “Parties.” 

WHEREAS, Fourteen22 has been formed as a wholly owned subsidiary of Moksha8 Inc., a Delaware corporation
and the sole shareholder of Moksha8, and holds legal title to all assets of the biosimilars business formerly owned by Moksha8, including the rights to specific biosimilar Products (defined below), and it is currently contemplated that following the
execution of this Agreement, Moksha8, Fourteen22 and certain third-party investors are entering into that certain Series A Preferred Stock and Warrant Purchase Agreement (the “Stock Purchase Agreement”) and related
documents (collectively, with the Stock Purchase Agreement, the “Financing Documents”) with respect to the financing of Fourteen22; and 

WHEREAS, in full payment of Fourteen22’s obligations under that certain Promissory Note dated as of May 14, 2009 (including
all principal and accrued and unpaid interest thereon), issued by Fourteen22 to Moksha8 in the amount of $[***] (“Note”), and as consideration for the cancellation of the Note, Fourteen22 is willing to provide
to Moksha8 and Moksha8 desires to receive, a revenue stream on the Net Sales of Products (as defined below) and certain rights of negotiation with respect to the Products in the M8 Territory (defined below), all as and to the extent set out
below; 
 NOW, THEREFORE, in consideration of the mutual covenants and obligations contained herein and for other good and
valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Parties, intending to be legally bound, agree as follows: 

ARTICLE I  

DEFINITIONS; CERTAIN RULES OF CONSTRUCTION 

Section 1.1 Defined Terms. 

As used in this Agreement, the following terms shall have the following meanings (such meanings to be equally applicable to both the singular
and plural forms of the terms defined): 
 “013 Product” means any drug product for use in humans
which is a Biosimilar to Humira (adalimumab) and that is manufactured using cell lines derived from those certain cell clones originally provided by M8 to Fourteen22 for such Product. 

“014 Product” means any drug product for use in humans which is a Biosimilar to Rituxan (rituximab) and
that is manufactured using cell lines derived from those certain cell clones originally provided by M8 to Fourteen22 for such Product. 

 “015 Product” means any drug product for use in humans
which is a Biosimilar to Remicade (infliximab) and that is manufactured using cell lines derived from those certain cell clones identified as the ‘015 Master Cell Bank / Working Cell Bank (MCB/WCB) originally provided by Moksha8 to Fourteen22
for such Product. 
 “AAA” shall have the meaning set forth in Section 9.11. 

“Affiliate” shall mean, with respect to any Person, any other Person directly or indirectly controlling
or controlled by or under common control with such Person. A Person shall be deemed to “control” another Person if such Person (i) possesses, directly or indirectly, the power to vote 50% or more of the securities having ordinary
voting power for the election of directors (or persons performing similar functions) of such other Person or, (ii) possesses, directly or indirectly, the power to direct or cause the direction of the management or policies of such other Person,
whether through the ownership of voting securities, by contract or otherwise. Notwithstanding the above, the term “Affiliate” with respect to Moksha8 [***], Fourteen22 or [***] or Fourteen22, Inc., or [***]. 

“Applicable Law” shall mean, with respect to any Person, all provisions of laws, statutes, ordinances,
rules, regulations, permits or certificates of any Governmental Authority applicable to such Person or any of its assets or property, and all judgments, injunctions, orders and decrees of all courts, arbitrators or Governmental Authorities in
proceedings or actions in which such Person is a party or by which any of its assets or properties are bound. 

“Biosimilar” means with respect to a given Product, any pharmaceutical biologic product that (a) is
[***], such that [***], and (b) has [***]. 
 “Catalent Agreement” means that
certain GPEX Cell Line Sale Agreement entered by and between Catalent pharma Solutions LLC and Moksha8 pharmaceuticals, Inc. as of January 1, 2009, that was assigned by Moksha8 Pharmaceuticals, Inc. to Fourteen22, Inc. pursuant to that certain
Asset Transfer Agreement entered by such entities as of May 14, 2010. 
 “Change of
Control” shall mean, with respect to a Party, the occurrence of any of the following events: (i) any corporation or other person or entity is or becomes the “beneficial owner” (as such term is used in Sections 12(d)
and 13(d) of the Securities Exchange Act of 1934, as amended, except that a corporation or other entity shall be deemed to have “beneficial ownership” of all shares that any such corporation or other entity has the right to acquire,
whether such right may be exercised immediately or only after the passage of time), of a majority of the total voting power represented by all classes of capital stock then outstanding of such Party normally entitled to vote in elections of
directors of the Party; (ii) such Party consolidates with or merges into another corporation or entity, or any corporation or entity consolidates with or merges into such Party in any merger, reorganization, consolidation or business
combination involving such Party that results in the holders of beneficial ownership of the voting securities or other voting interests of such Party (or, if applicable, the ultimate parent of such Party) immediately prior to such merger,
reorganization, consolidation or business combination ceasing to hold beneficial ownership of at least fifty percent (50%) of the combined voting power of the surviving entity immediately after such merger, reorganization, consolidation or
business combination; and (iii) such Party conveys, transfers or leases all or substantially all of its assets to any corporation or other entity other than a wholly-owned subsidiary of such Party in one or more related transactions.

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 “Confidential Information” shall have the meaning set forth in
Section 7.1. 
 “Cure Period” shall have the meaning set forth in Section 8.2. 

“Effective Date” shall have the meaning set forth in the Preamble. 

“First Commercial Sale” shall mean with regard to a particular Product, the first commercial sale by Fourteen22 or its
Affiliate or a licensee of Fourteen22 of such Product in a country in the Territory for use, consumption or resale to any Third Party customer [***] with respect to the [***] of such Product have [***], including without limitation, [***]. 

“Force Majeure” shall have the meaning set forth in Section 9.15. 

“Fourteen22” shall have the meaning set forth in the Preamble. 

“Fourteen22 Indemnified Parties” shall have the meaning set forth in Section 6.1. 

“Governmental Authority” shall mean any federal, state or local government, and any legislative, judicial or executive
body thereof, governmental regulator or administrative authority (or subdivision thereof) and any agency, authority, instrumentality, regulatory body or commission (including antitrust authorities) or any court, tribunal or judicial or arbitral body
that has jurisdiction over a Party’s business or its assets. 
 “Indemnification Claim Notice” shall have the
meaning set forth in Section 6.3(a). 
 “Indemnified Party” shall have the meaning set forth in
Section 6.3(a). 
 “Indemnifying Party” shall have the meaning set forth in Section 6.3(a). 

“Innovator Product” means the following: 

(a) As to the ‘013 Product, Humira (adalimumab) 

(b) As to the ‘014 Product, Rituxan (rituximab) 

(c) As to the ‘015 Product, Remicade (infliximab) 

“Licensing Revenue” means with respect to a given Product, any royalties, profit-share or other
recurring cash payments, including upfront and milestone payments, received by Fourteen22 or its Affiliates from a Third Party licensee or distributor of such Product in exchange for the right to commercialize, promote or sell such Product by such
Third Party (a “Third Party Partner”), less, in each case, any amounts due by Fourteen22 to one or more Third Parties for license or other rights necessary to manufacture or commercialize such Product in the relevant country and/or
field (to the extent not reimbursed or paid directly by, such Third Party Partner), including without limitation, payments due from Fourteen22 to Catalent Pharma 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
Solutions LLC under the Catalent Agreement with regard to the sale of such Product by such Third Party Partner. In addition, Licensing Revenues shall not include any amount received by
Fourteen22 or its Affiliates from any Third Party Partner for (a) the conduct or performance of any activities conducted after the Effective Date relating to the research and/or development of any Product or any product other than a Product, or
(b) the sale of any product other than a Product, or (c) any option, license or other grant of rights of any intellectual property related to any product other than a Product, (d) the sale of any units of Product or bulk drug
substance by Fourteen22 or its Affiliates to a Third Party Partner, or (e) for the purchase of any equity securities of Fourteen22 or its Affiliates or for the issuance of debt by any such entity. 

“Losses” shall have the meaning set forth in Section 6.1. 

“Moksha8” shall have the meaning set forth in the Preamble. 

“Moksha8 Indemnified Parties” shall have the meaning set forth in Section 6.2. 

“Net Sales” means, with respect to any Product, the gross amount [***] by Fourteen22, or any Fourteen22 Affiliate (the
“Selling Party”) for sales of such Product in the Territory to a Third Party, less deductions for the following, to the extent included in [***] or otherwise actually allowed or incurred with respect to such sales: 

(i) transportation charges, and other charges, such as insurance, incurred for delivery of such Product, 

(ii) sales and excise taxes or customs duties incurred by the Selling Party and any other governmental charges imposed upon the sale of such
Product and incurred by the Selling Party, 
 (iii) rebates or allowances actually granted or allowed, including government and managed
care rebates, 
 (iv) discounts (including quantity discounts and cash discounts), cash and non-cash coupons, retroactive price reductions,
chargeback payments, bad debt, and rebates actually taken, granted, allowed or incurred [***] in connection with the sale of such Product, including discounts or rebates to governmental agencies or instrumentalities or to Managed Care Organizations,

 (v) allowances or credits actually granted or given [***], on account of claims, damaged goods, rejection, recalls or withdrawals, or
outdating return of such Product, and 
 (vi) any payments due to Third Parties for license or other rights necessary to manufacture or
commercialize such Product, including without limitation, payments due from Fourteen22 to Catalent Pharma Solutions LLC under the Catalent Agreement. 

If the Selling Party makes any adjustments to such deductions after the associated Net Sales have been reported pursuant to this Agreement,
the adjustments shall be reported and 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
reconciled with the next report and payment of any revenue due. Sales between Fourteen22 and its Affiliates shall be disregarded for purposes of calculating Net Sales except if such purchaser is
an end user. For clarity, sales by Fourteen22 or its Affiliates to a Third Party distributor, wholesaler, group purchasing organization, pharmacy benefit manager, or retail chain customer shall be considered sales to a Third Party. 

With respect to any sale of any Product in a given country by Fourteen22 for any substantial consideration other than monetary
consideration on arm’s length terms (which has the effect of reducing the invoiced amount below what it would have been in the absence of such non-monetary consideration), for purposes of calculating the Net Sales under this Agreement, such
Product shall be deemed to be sold [***] during the [***]; provided that, notwithstanding the foregoing, Net Sales shall not include amounts (whether actually existing or deemed to exist for purposes of calculation) for Products
(x) distributed for use in clinical trials, or (y) provided pursuant to an early access, compassionate use, indigent access or patient assistance program (except to the extent of any amounts actually received from Third Parties on account
of same). 
 In the case of discounts on “bundles” of products including but not limited to Products, Fourteen22 and
any other Selling Party may discount the bona fide list price of a Product [***] calculated as follows: 
  

					
		 		 	[***]

 where A equals the [***] of a [***], and B equals the [***] of the [***]. Fourteen22 shall retain documentation, establishing
such [***]. If Fourteen22 cannot so establish the [***], Net Sales shall be based on the [***] of the [***]. If a Product in a “bundle” is [***], then the [***] and Net Sales with respect thereto shall be [***]. 

If Fourteen22 or any Affiliate sells any Product as part of a combination product containing one or more pharmaceutically active ingredients
or a delivery device in addition to the Product (whether combined in a single formulation and/or package, as applicable, or formulated and/or packaged separately, (such product, a “Combination Product”), Net Sales of such Combination
Product will be calculated by [***] of such [***] is the [***] of the [***], and [***] of the [***] or the [***] in the Combination Product, [***]. 

If, on a country-by-country basis, such other pharmaceutically active ingredient or ingredients or delivery device in the Combination Product
are not sold separately in such country, but the Product is sold separately in such country, Net Sales for the purpose of determining amounts owed under Section 2.1 on the Combination Product shall be calculated by [***] of such [***] is the
[***] of the [***], and [***] of the Combination Product. If, on a country-by-country basis, such Product is not sold separately in such country, Net Sales for the purposes of determining amounts owed under Section 2.1 on the Combination
Product shall be [***] is the [***] of the [***] is the [***] of the [***] of the [***] in such combination Product, as such [***] are determined [***]. 

Net Sales shall be determined in accordance with those generally accepted accounting principles (in accordance with GAAP, or as applicable,
IFRS) consistently employed by Fourteen22 or its Affiliates, as the case may be, with respect to external reporting. 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 “M8 Territory” shall mean the countries of Latin America listed on
Exhibit A [***] that the [***] pursuant to Section [***]. 
 “Parties” shall have the meaning set forth in
the Preamble. 
 “Person” shall mean and include natural persons, corporations, limited partnerships, general
partnerships, limited liability companies, joint stock companies, joint ventures, associations, companies, trusts, banks or other organizations, whether or not legal entities, and governments and agencies and political subdivisions thereof. 

“Product(s)” means any or all of the 013 Product, the 014 Product and the 015 Product. 

“Product Transaction” means, with respect to a particular Product, a transaction involving the grant by Fourteen22 or
its Affiliate of a license to Moksha8 or a Third Party to market, distribute, sell, promote or otherwise commercialize such Product in one or more countries of the Territory. 

“Regulatory Approval” means all approvals necessary for the manufacture, marketing, importation, exportation and sale
of a Product for one or more indications and in a country or regulatory jurisdiction, which may include, without limitation, satisfaction of all applicable regulatory and notification requirements, as well as any pricing and reimbursement approvals.

 “Term” shall have the meaning set forth in Section 8.1. 

“Territory” shall mean all of the countries of the world, excluding those countries of the M8 Territory in which M8
obtains a license to sell or otherwise commercialize pursuant to the exercise of its rights of first negotiation under Section 3.1. 

“Third Party” shall mean any Person other than Fourteen22 and its Affiliates, or Moksha8 and its Affiliates. 

“Third Party Claim” shall have the meaning set forth in Section 6.1. 

Section 1.2 Rules of Construction. 

(a) Any term defined herein in the singular form shall have a comparable meaning when used in the plural form, and vice versa. 

(b) When used herein, the words “hereof,” “herein” and “hereunder” and words of similar import when used in this
Agreement shall refer to this Agreement as a whole and not to any particular provision of this Agreement. References to the Preamble, Recitals, Articles, Sections, Schedules or Appendices shall refer respectively to the Preamble, Recitals, Articles,
Sections, Schedules or Appendices of this Agreement, unless otherwise expressly provided. 
 (c) When used herein, the terms
“include,” “includes,” and “including” are not limiting. 
 (d) Unless the context requires otherwise,
derivative forms of any term defined herein shall have a comparable meaning to that of such term. 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 “Upfront and Milestone Payments” has the meaning set forth in
Section 2.4. 
 ARTICLE II 

REVENUE SHARING PAYMENTS 

Section 2.1 Revenue Payable to Moksha8 on Net Sales by Fourteen22 or its Affiliates. Subject to the terms and conditions of this
Agreement, including without limitation, Section 2.3, Fourteen22 shall pay to Moksha8 sales-based payments based on a percentage of the Net Sales of the applicable Product in the Territory made by Fourteen22 or its Affiliates, as set forth
below. 
 (a) Payment for 013 Products. Commencing on the date of First Commercial Sale of the 013 Product in the Territory,
Fourteen22 shall make payments to Moksha8 on the Net Sales of the 013 Product in the Territory by Fourteen22 or its Affiliates, as follows: 
  

					
	 [***]
	  	Revenue
Percentage	 
	 [***]
	  	 	[***	]% 
	 [***]
	  	 	[***	]% 

 (b) Payment for 014 Products. Commencing on the date of First Commercial Sale of the 014 Product
in the Territory, Fourteen22 shall make payments to Moksha8 on the Net Sales of the 014 Product in the Territory by Fourteen22 or its Affiliates, as follows: 
  

					
	 [***]
	  	Revenue
Percentage	 
	 [***]
	  	 	[***	]% 
	 [***]
	  	 	[***	]% 

 (c) Payment for 015 Products. Commencing on the date of First Commercial Sale of the 015 Product
in the Territory, Fourteen22 shall make payments to Moksha8 on the Net Sales of the 015 Product in the Territory by Fourteen22 or its Affiliates, as follows: 
  

					
	 [***]
	  	Revenue
Percentage	 
	 [***]
	  	 	[***	]% 
	 [***]
	  	 	[***	]% 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 Section 2.2 Revenue Payable to Moksha8 on Licensing Revenue. Subject to
the terms and conditions of this Agreement, including without limitation Section 2.3, Fourteen22 shall pay to Moksha8 a percentage of Licensing Revenue received by Fourteen22 or its Affiliates from a Third Party for the applicable Product, in a
particular calendar year, as follows: 
 (a) 013 Product. With respect to the 013 Product, [***] percent ([***]%) of Licensing
Revenues for such Product until cumulative total paid to Moksha8 for such Product [***] equals $[***], and thereafter such payments shall be reduced to [***]% of Licensing Revenues from such Product [***]; 

(b) 014 Product. With respect to the 014 Product, [***]% of Licensing Revenues for such Product until cumulative total paid to
Moksha8 for such Product [***] equals $[***], and thereafter such payments shall be reduced to [***]% of Licensing Revenues for such Product [***]; 

(c) 015 Product. With respect to the 015 Product, [***]% of Licensing Revenues for such Product until cumulative total paid to
Moksha8 for such Product [***] equals $[***], and thereafter such payments shall be reduced to [***]% of Licensing Revenues for such Product [***]. 

To the extent any given agreement with a Third Party Partner involves more than one Product, amounts received thereunder that are not specifically allocated
to a given Product shall be allocated [***], unless such allocation is specified in the agreement between Fourteen22 and the Third Party Partner. For example and without limitation, if an upfront payment of $5,000,000 was made under any such
agreement involving a license to the 015 Product and the 013 Product without allocation between such Products, then [***], and the [***] unless otherwise agreed by the Parties hereto. 

Section 2.3 Aggregation. The cumulative amounts due to Moksha8 with respect to (a) sales of Products made by
Fourteen22 and its Affiliates pursuant to Section 2.1, and (b) the payment of a percentage of Licensing Revenues pursuant to Section 2.2, shall be limited as follows: 

(a) 013 Product. With respect to the 013 Product, once the [***] pursuant to Section 2.1 and/or Section 2.2 equal
$[***], then for the [***] the amounts due to Moksha8 with respect to such Product shall be reduced to (i) [***] percent ([***]%) of Net Sales of such Product, and (ii) [***] percent ([***]%) of Licensing Revenues received by Fourteen22
and its Affiliates for such Product. 
 (b) 014 Product. With respect to the 014 Product, once the [***] pursuant to
Section 2.1 and/or Section 2.2 equal $[***], then for the [***] the amounts due to Moksha8 with respect to such Product shall be reduced to (i) [***] percent ([***]%) of Net Sales of such Product, and (ii) [***] percent ([***]%)
of Licensing Revenues received by Fourteen22 and its Affiliates for such Product. 
 (c) 015 Product. With respect to
the 015 Product, once the [***] pursuant to Section 2.1 and/or Section 2.2 equal $[***], then for the [***] the amounts due to Moksha8 with respect to such Product shall be reduced to (i) [***] percent ([***]%) of Net Sales of such
Product, and (ii) [***] percent ([***]%) of the Licensing Revenues received by Fourteen22 and its Affiliates for such Product. 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 Section 2.4 Deferral. With respect to that portion of any Licensing Revenue
consisting of upfront or milestone payments paid prior to the First Commercial Sale (whether by Fourteen22 or its Third Party Partner) of a particular Product that is subject to such Third Party Partner arrangement giving rise to such payments (the
“Upfront and Milestone Payments”), Fourteen22 shall have the option to defer the amount owed to Moksha8 pursuant to Sections 2.2 and 2.3 above with respect to each such Upfront and Milestone Payment [***], in which event the
amount then owed at the time of payment would be equal to the amount deferred and owed, [***]; provided, however, that in each such calendar quarter in which one or more such Upfront and Milestone Payments is being deferred, Fourteen22 shall [***],
within [***] of Moksha8’s notice to Fourteen22 of [***]. 
 Section 2.5 Acknowledgement. Moksha8 acknowledges and agrees
that (a) the payments set forth in Section 2.1 and 2.2 are the sole financial consideration due to Moksha8 with respect to the development and/or commercialization of any Products, (b) there is no assurance that any of the Products
will be developed or approved for commercial sale, or successfully commercialized if approved for commercial sale, and (c) Moksha8 shall have no recourse if it does not receive payments under Section 2.1 or 2.2 due to a decision by
Fourteen22 or a Fourteen22 designee or licensee not to develop or commercialize any Product. For clarity, if Products are commercialized by Fourteen22 or an Affiliate, Moksha8 shall receive the applicable payments described in Section 2.1; if
instead Fourteen22 licenses its rights to a given Product to a Third Party Partner for a particular country or territory, Moksha8 shall receive the applicable Licensing Revenue payments described in Section 2.2, as and to the extent Fourteen22
or its Affiliates receives Licensing Revenue therefore. 
 Section 2.6 Revenue Payment Term. Fourteen22’s payment
obligations under Sections 2.1(a)-(c) will expire, on a country by country and Product by Product basis, upon the date that is the tenth
(10th) anniversary of the First Commercial Sale of such Licensed Product. Fourteen22 will notify Moksha8 promptly after the First Commercial Sale of a Licensed Product. Fourteen22’s
payment obligations under Section 2.2 shall expire upon the tenth (10th) anniversary of the First Commercial Sale of such Product. 

Section 2.7 Payment and Reporting. Any payments due Moksha8 under Section 2.2, to the extent not deferred pursuant to
Section 2.4, shall be paid within [***] of receipt of any Licensing Revenue by Fourteen22 or its Affiliates. With respect to payments due under Section 2.1, within [***] following the end of each calendar quarter for which such payment is
due, Fourteen22 shall furnish, or cause to be furnished to Moksha8, (i) payment of all revenues owed to Moksha8 during such quarter; and (ii) a detailed written report setting forth, as to each Product: 

(a) the calculation of Net Sales during the most recent calendar quarter in the Territory, including the number of units of such Product sold,
detail with respect to deductions taken in calculating Net Sales, and gross sales of such Product; 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 (b) the applicable exchange rate to convert from each country of sale’s currency to US
dollars under Section 2.4 hereof; and 
 (c) the revenue payments payable in U.S. Dollars, which shall have accrued hereunder in
respect to such Net Sales in the Territory. 
 Section 2.8 Payments. 

(a) All payments to be made by Fourteen22 to Moksha8 shall be in US dollars by wire transfer in immediately available funds to an account
designated by Moksha8. Fourteen22 shall keep accurate records in sufficient detail to enable revenues and other payments payable hereunder to be determined. When converting payments due under this Agreement from local currency to U.S. Dollars, the
Parties shall use [***] or other source mutually agreed by the Parties) during the applicable time period. For sales of Product that occur in a currency other than US dollars, following conversion of each local currency to US dollars, the quarterly
Net Sales in US dollars shall be summed, with payments calculated according to the revenue percentages applicable to such Net Sales under this Agreement. 

(b) If by law, regulation or fiscal policy of a particular country in the Territory, remittance of payment in US dollars to Moksha8 is
restricted or forbidden, written notice, including details of such legal restriction, will be promptly provided to Moksha8, and payment shall be made by the deposit thereof in local currency to the credit of Moksha8 in a recognized banking
institution designated by Moksha8 in writing. 
 (c) Any payment due hereunder and not paid on or before the specified due date shall bear
interest, to the extent permitted by applicable law, at a rate equal to the sum of [***] percent ([***]%) [***]. 
 Section 2.9
Taxes. Fourteen22 shall withhold and deduct from all payments made pursuant to this Agreement any tax amounts required to be withheld and deducted from such payments under applicable law and in accordance with this Section. Any amounts so
withheld and deducted shall be remitted by Fourteen22 on a timely basis to the appropriate Governmental Authority for the account of Moksha8 and Fourteen22 shall provide Moksha8 reasonable evidence of such remittance and payment on its behalf within
[***] of such remittance. To the extent that amounts are so withheld, such withheld amounts shall be treated for all purposes of this Agreement as having been paid to Moksha8 in respect of which such deduction and withholding was made by Fourteen22.
Moksha8 shall furnish to Fourteen22 such forms, certificates and documentation (including, without limitation, Internal Revenue Service Form W-9) as may be necessary or appropriate to obtain any reduction
of, credit for, or exemption from any withholding and Fourteen22 shall use commercially reasonable efforts to obtain any such reduction, credit or exemption. 

Section 2.10 Records; Right to Audit. 

(a) Fourteen22 agrees to keep full, clear and accurate records for a period of at least [***] after any payment made or received by Moksha8
under this Agreement, or such longer period as may coincide with Fourteen22’s internal records retention policy or Applicable 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
Law. Such records shall contain all information reasonably necessary for calculating any payments due from Fourteen22 under this Agreement. Fourteen22 further agrees, on [***] prior written
notice from Moksha8, to permit its financial books and records to be examined by an independent accounting firm selected by Moksha8 (and reasonably acceptable to Fourteen22) from time to time (but in no event more than once per calendar year) solely
to the extent reasonably necessary to verify the correctness of the calculation of the Net Sales and the revenues due Moksha8 hereunder. The accounting firm shall be provided access to such financial records at Fourteen22’s facility(ies) where
such financial records are normally kept and such examination shall be conducted during Fourteen22’s normal business hours. Fourteen22 may require the accounting firm to sign a standard non-disclosure agreement before providing the accounting
firm access at its facilities or records. Upon completion of the audit, the accounting firm shall provide both Parties a written report disclosing any discrepancies in the reports submitted by Fourteen22 or the revenues paid by it, if any, and, in
each case, the specific details concerning any discrepancies. 
 (b) If such independent public accounting firm’s written report shows
any underpayment of revenue payments due hereunder, Fourteen22 shall remit to Moksha8 within [***] after Fourteen22’s receipt of such report so concluding (or, if later, within [***] after resolution of a bona fide objection by Fourteen22 to
the findings in such report), (i) the amount of such underpayment and (ii) if such underpayment exceeds [***] percent ([***]%) of the total amount owed to Moksha8 for the year(s) then being examined, the reasonable fees and expenses of
such independent public accountant performing the examination, subject to reasonable substantiation thereof. If such independent public accounting firm’s written report shows any overpayment of revenue payments due hereunder, Fourteen22 shall
receive a credit equal to such overpayment against the payments otherwise payable to Moksha8 under this Agreement. 
 (c) This
Section 2.10 shall survive for a period of [***] after the termination or expiration of this Agreement. 
 Section 2.11 Change
of Control or Assignment. For the avoidance of doubt, the revenue sharing obligation set forth in this Article 2 shall remain in effect and be binding obligations of such surviving entity or assignee, as the case may be (subject to the
terms and conditions set forth in this Agreement) regardless of whether Fourteen22 undergoes a Change of Control, or assigns all its rights in and to a particular Product to a Third Party. 

ARTICLE III 
 RIGHT
OF NEGOTIATION 
 Section 3.1 Rights of Negotiation. 

(a) On a Product-by-Product basis, subject to the limitation in Section 3.1(e), if at any time within the first five
(5) years following the Effective Date (the “RON Period”), Fourteen22 desires to negotiate and enter into a Product Transaction with respect to one or more countries in the M8 Territory, then it shall provide notice
thereof to Moksha8 (the “Product Transaction Notice”). Similarly, at any time during the RON Period, if Moksha8 desires to negotiate and enter into a license agreement with Fourteen22 with respect to any Product with

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
respect to one or more countries in the M8 Territory, then it may provide notice thereof to Moksha8 (“Moksha8 Notice”). For clarity, it
is anticipated that Moksha8 shall provide such a Moksha8 Notice within [***] of the Effective Date. 
 (b) Within the [***]
period following the receipt of any Product Transaction Notice, Moksha8 shall notify Fourteen22 in writing whether it desires to exercise its right of negotiation with respect to a particular Product with respect to one or more countries in the M8
Territory. 
 (c) If, for any Product (i) Moksha8 timely notifies Fourteen22 that it wishes to exercise its right to
negotiate following any Product Transaction Notice or (ii) Moksha8 provides to Fourteen22 a Moksha8 Notice, Fourteen22 and Moksha8 shall promptly enter into good faith negotiations, for a period not to exceed [***], with respect to the terms of
such a Product Transaction (the “Negotiation Period”), which period may be extended by mutual written consent of the Parties. It is understood and agreed that Moksha8’s right of negotiation provided in this
Section 3.1 is non-exclusive, and at all times, Fourteen22 shall be free, without restriction, to negotiate and enter into agreements with Third Parties for any Product(s) for any countries. 

(d) At any time during the term of this Agreement, Moksha8 may propose to Fourteen22 that [***] and in such event the Parties [***]. If the
Parties agree to [***], such agreement shall be reflected in writing. 
 (e) The rights granted to Moksha8 in this Section 3.2 shall
terminate upon any Change of Control of Fourteen22. 
 ARTICLE IV  

CONSIDERATION 

Section 4.1 Extinguishment of Debt; Termination of Previous Agreements. 

In consideration for the payments, rights and obligations as set forth in Article II and Article III hereof, the Parties and their
Affiliates agree to, and hereby do terminate, cancel and extinguish the Note. The Parties agree to cooperate to perfect such termination, cancellation and extinguishment by separate instrument as reasonably requested. 

Section 4.2 Sufficiency of Consideration. 

Each Party agrees that the consideration provided to Fourteen22 by Moksha8 pursuant to Section 4.1, and the payments that may be made to
Moksha8 by Fourteen22 pursuant to Section 2.1, are full and sufficient consideration for the benefits that the respective Parties will or may receive under this Agreement 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 ARTICLE V  

REPRESENTATIONS AND WARRANTIES 

Section 5.1 Mutual Representations and Warranties. 

Each Party hereby represents and warrants to the other Party as follows as of the Effective Date: 

(a) Such Party is duly formed and in good standing under the laws of the jurisdiction of its formation; 

(b) Such Party has the power and authority and the legal right to enter into this Agreement and perform its obligations hereunder; 

(c) Such Party has taken all necessary action on its part required to authorize the execution and delivery of this Agreement and the
performance of its obligations hereunder; 
 (d) This Agreement has been duly executed and delivered on behalf of such Party and constitutes
a legal, valid and binding obligation of such Party and is enforceable against it in accordance with its terms; and 
 (e) The execution and
delivery of this Agreement and the performance of such Party’s obligations hereunder (i) do not conflict with or violate any requirement of any Applicable Laws or any provision of the charter documents of such Party and (ii) do not
conflict with, violate, or breach, or constitute a default or require any consent under, any material contractual obligation or court or administrative order by which such Party is bound. 

Section 5.2 Moksha8. As of the Effective Date, Moksha8 represents and warrants that no payments shall be due from or payable by
Fourteen22 to Moksha8 or any of its Affiliates with respect to the Note and that on or before the execution of the Financing Documents no other payments shall be due from or payable by Fourteen22 or any of its Affiliates to Moksha8 or any of its
Affiliates, except as otherwise expressly agreed in writing by the Parties after the Effective Date of this Agreement. 

Section 5.3 No Implication. Except as expressly stated herein, nothing in the Agreement shall be construed as: 

(a) A warranty or representation by [***] of any of the [***] to Fourteen22 with respect to [***]; or 

(b) A warranty or representation by [***] is or shall be [***]. 

Section 5.4 Disclaimer. 

EXCEPT AS EXPRESSLY SET FORTH HEREIN, EACH PARTY EXPRESSLY DISCLAIMS ANY AND ALL WARRANTIES OF ANY KIND, EXPRESS OR IMPLIED,

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
INCLUDING WITHOUT LIMITATION THE WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, AND NONINFRINGEMENT OF THIRD PARTY INTELLECTUAL PROPERTY RIGHTS. 

Section 5.5 Limitation of Liability. 

NEITHER PARTY SHALL BE ENTITLED TO RECOVER FROM THE OTHER PARTY ANY LOST PROFITS OR SPECIAL, INCIDENTAL, CONSEQUENTIAL OR PUNITIVE DAMAGES IN
CONNECTION WITH THIS AGREEMENT [***]. 
 ARTICLE VI  

INDEMNIFICATION 

Section 6.1 Moksha8 Indemnification. 

Moksha8 shall indemnify Fourteen22, its Affiliates and its and their respective directors, officers, employees and agents (the
“Fourteen22 Indemnified Parties”), and defend and hold each of them harmless, from and against any and all losses, damages, judgments, liabilities, penalties, costs and expenses (including reasonable attorneys’ fees and
disbursements) (collectively, “Losses”) resulting from any Third Party claims, allegations, actions, lawsuits, or proceedings (collectively, “Third Party Claims”) against any of them arising from or
occurring as a result of: (a) the breach by Moksha8 of this Agreement, including without limitation any representation or warranty in Article 5; (b) the [***] intentional misconduct of Moksha8, its Affiliates and its and their
employees and agents [***]; or (c) the exploitation by Moksha8 and/or Fourteen22 and/or their respective Affiliates [***] of any intellectual property assigned to Fourteen22 by Moksha8 or its Affiliates, or otherwise arising out of the
development and commercialization of any Biosimilar or other product [***], including claims for personal injury, property damage, and infringement of intellectual property rights; and except, in each case, to the extent that Fourteen22 has an
obligation to indemnify the Moksha8 Indemnified Parties pursuant to Section 6.2. 
 Section 6.2 Fourteen22
Indemnification. 
 Fourteen22 shall indemnify Moksha8, its Affiliates and its and their respective directors, officers,
employees and agents (the “Moksha8 Indemnified Parties”), and defend and hold each of them harmless, from and against any and all Losses resulting from any Third Party Claims against any of them arising from or occurring as a
result of (a) the breach by Fourteen22 of this Agreement, including without limitation any representation or warranty in Article 5; (b) the [***] intentional misconduct of Fourteen22, its Affiliates and its and their employees and
agents after the Effective Date; (c) the exploitation or other use by Fourteen22 or its Affiliates or designees or licensees after the Effective Date of any intellectual property assigned to it by Moksha8 or its Affiliates, or otherwise arising
out of the development and commercialization of any Biosimilar or other product after the Effective Date, including claims for personal injury, property damage, and infringement of intellectual property rights, such Losses except, to the extent that
(x) Moksha8 has an obligation to indemnify the Fourteen22 Indemnified Parties pursuant to Section 6.1, or (y) such Losses that arise from or are subject to a license or other agreement, if any, entered into by Fourteen22 and Moksha8
pursuant to Section 3.1. 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 Section 6.3 Indemnification Procedure. 

(a) Notice of Claim. The indemnified party (the “Indemnified Party”)
shall give the indemnifying Party (the “Indemnifying Party”) prompt written notice (an “Indemnification Claim Notice”) of any Losses or discovery of facts upon which such Indemnified Party intends to
base a request for indemnification under Section 6.1 or 6.2 but [***]. Each Indemnification Claim Notice must contain a description of the claim and the nature and amount of such Losses (to the extent that the nature and amount of such Losses
are known at such time). The Indemnified Party shall furnish promptly to the Indemnifying Party copies of all papers and official documents received in respect of any Losses. 

(b) Third Party Claims. The obligations of an Indemnifying Party under this Article VI with respect to Losses arising from
any Third Party Claims that are subject to indemnification as provided for in Section 6.1 or 6.2 shall be governed by and be contingent upon the following additional terms and conditions: 

(i) Control of Defense. At its option, the Indemnifying Party may assume the defense of any Third Party Claim by giving written notice
to the Indemnified Party within [***] after the Indemnifying Party’s receipt of an Indemnification Claim Notice. The assumption of the defense of a Third Party Claim by the Indemnifying Party shall not be construed as an acknowledgment that the
Indemnifying Party is liable to indemnify any Indemnified Party in respect of the Third Party Claim, nor shall it constitute a waiver by the Indemnifying Party of any defenses it may assert against any Indemnified Party’s claim for
indemnification. Upon assuming the defense of a Third Party Claim, the Indemnifying Party may appoint as lead counsel in the defense of the Third Party Claim any legal counsel selected by the Indemnifying Party, which shall be reasonably acceptable
to the Indemnified Party (the Indemnified Party’s consent to such legal counsel not to be unreasonably withheld, conditioned or delayed). In the event the Indemnifying Party assumes the defense of a Third Party Claim, the Indemnified Party
shall immediately deliver to the Indemnifying Party all original notices and documents (including court papers) received by any Indemnified Party in connection with the Third Party Claim. Subject to clause (ii) below, if the Indemnifying Party
assumes the defense of a Third Party Claim, the Indemnifying Party shall not be liable to the Indemnified Party for any legal expenses subsequently incurred by such Indemnified Party in connection with the analysis, defense or settlement of the
Third Party Claim. To the extent that it is ultimately determined that the Indemnifying Party is not obligated to indemnify, defend or hold harmless an Indemnified Party from and against the Third Party Claim, the Indemnified Party shall, within
[***] following such ultimate determination, reimburse the Indemnifying Party in full for any and all costs and expenses (including reasonable attorneys’ fees and costs of suit) incurred by the Indemnifying Party in its defense of the Third
Party Claim with respect to such Indemnified Party. 
 (ii) Right to Participate in Defense. Without limiting
Section 6.3(b)(i), any Indemnified Party shall be entitled to participate in, but not control, the 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
defense of such Third Party Claim and to employ counsel of its choice for such purpose; provided, however, that such employment shall be at the Indemnified Party’s own expense
unless (A) the employment thereof has been specifically authorized by the Indemnifying Party in writing, (B) the Indemnifying Party has failed to assume the defense and employ counsel in accordance with Section 6.3(b)(i) (in which
case the Indemnified Party shall control the defense), or (C) the interests of the Indemnified Party and the Indemnifying Party with respect to such Third Party Claim are sufficiently adverse to prohibit the representation by the same counsel
of both Parties under applicable law or ethical rules governing legal representation in the jurisdiction at issue. 
 (iii)
Settlement. With respect to any Losses relating solely to the payment of money damages in connection with a Third Party Claim and that will not result in the Indemnified Party’s becoming subject to injunctive or other relief, and as to
which the Indemnifying Party shall have acknowledged in writing the obligation to indemnify the Indemnified Party hereunder, the Indemnifying Party shall have the sole right to consent to the entry of any judgment, enter into any settlement or
otherwise dispose of such Loss, on such terms as the Indemnifying Party, in its sole discretion, shall deem appropriate. With respect to all other Losses in connection with Third Party Claims, where the Indemnifying Party has assumed the defense of
the Third Party Claim in accordance with Section 6.3(b)(i), the Indemnifying Party shall have authority to consent to the entry of any judgment, enter into any settlement or otherwise dispose of such Loss; provided that it obtains the prior
written consent of the Indemnified Party (which consent shall not be unreasonably withheld, delayed or conditioned). The Indemnifying Party shall not be liable for any settlement or other disposition of a Loss by an Indemnified Party that is reached
without the written consent of the Indemnifying Party. Regardless of whether the Indemnifying Party chooses to defend or prosecute any Third Party Claim, no Indemnified Party shall admit any liability with respect to, or settle, compromise or
dispose of, any Third Party Claim without the prior written consent of the Indemnifying Party (which consent shall not be unreasonably withheld or delayed). 

(iv) Cooperation. If the Indemnifying Party chooses to defend or prosecute any Third Party Claim, the Indemnified Party shall
cooperate in the defense or prosecution thereof and shall furnish such records, information and testimony, provide such witnesses and attend such conferences, discovery proceedings, hearings, trials and appeals as may be reasonably requested in
connection therewith. Such cooperation shall include access during normal business hours afforded to the Indemnifying Party to, and reasonable retention by the Indemnified Party of, records and information that are reasonably relevant to such Third
Party Claim, and making employees and agents available on a mutually convenient basis to provide additional information and explanation of any material provided hereunder, and the Indemnifying Party shall reimburse the Indemnified Party for all its
reasonable out-of-pocket expenses in connection therewith. 
 (v) Expenses. Except as provided above, the reasonable
and verifiable costs and expenses, including fees and disbursements of counsel, incurred by the Indemnified Party in connection with any Third Party Claim shall be reimbursed on a calendar quarter basis in arrears by the Indemnifying Party, without
prejudice to the Indemnifying Party’s right to contest the Indemnified Party’s right to indemnification and subject to refund in the event the Indemnifying Party is ultimately held not to be obligated to indemnify the Indemnified Party.

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 (vi) Insurance. Fourteen22 and Moksha8 shall obtain and maintain, during the term
of this Agreement, at its own cost and expense, with reputable and financially sound insurance carriers, comprehensive commercial general liability insurance, including product liability insurance, excess liability insurance, to cover
Fourteen22’s and Moksha8’s indemnification obligations hereunder, respectively, or self-insurance, in amounts consistent with its normal business practices and the activities contemplated hereunder. Each such policy or self-insurance shall
be in types and amount that are reasonable and customary in the pharmaceutical industry for companies engaged in similar business and operations and amounts that meet all contractual requirements of Fourteen22’s and Moksha8’s, as
applicable, vendors, distributors or other contractors. Maintenance of such insurance coverage will not relieve a Party of any responsibility under this Agreement for Losses in excess of such insurance limits or otherwise. For product
liability/completed operations, such insurance coverage will remain in effect for at least [***] after the termination or expiration of this Agreement. 

ARTICLE VII  

CONFIDENTIALITY 

Section 7.1 Secrecy Obligations; Definition. 

Each Party agrees to keep the other Party’s confidential information secret and confidential. “Confidential
Information” shall mean all oral and/or written information disclosed during negotiation and/or performance of this present Agreement. Confidential Information shall include, for example, information relating to the Products (which
shall be deemed Confidential Information solely of Fourteen22), market data, clients’ information, norms and procedures. The receiving party shall not disclose the other party’s Confidential Information, or use such Confidential
Information for any purpose other than those contemplated hereunder, without the prior written consent of the other Party, and the receiving Party shall be responsible for indemnification of the disclosing Party for any damage resulting from its
breach of the confidentiality obligation herein undertaken. The Parties shall ensure that their employees and agents respect the confidentiality duty herein agreed, and shall be responsible for any breach of such confidentiality obligations by those
individuals. The obligations of confidentiality and non-use contained herein shall not apply to any information that: 
 (a)
is in the public domain at the time of the disclosure or enters the public domain after disclosure, except if this occurs due to an act or omission of the receiving Party or its Affiliate; 

(b) is already known by the receiving Party or its Affiliate, as established by the contemporaneous written records of the receiving Party or
its Affiliate; 
 (c) is developed independently by the receiving Party or its Affiliate without reference to the Confidential Information,
as established by the contemporaneous written records of the receiving Party or its Affiliate; or 
 (d) is legitimately received from a
Third Party not in breach of any obligation of confidentiality. 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 Section 7.2 Exceptions to Non-Disclosure. 

Notwithstanding the above, the receiving Party may disclose Confidential Information pursuant to applicable law or a valid governmental order
or judicial order, but only to the extent actually required by said orders, provided that the receiving Party has (to the extent permitted by law) previously notified the disclosing Party in writing about the existence of said order, and has, used
reasonable efforts to the extent practicable to give the disclosing Party due time to seek a protective order or other measure for limiting or preventing disclosure, to the extent available to the disclosing party. The receiving Party may also
disclose Confidential Information without authorization of the Disclosing Party to its Affiliates or agents on a need-to-know basis for purposes of carrying out its and their respective obligations hereunder (subject to any such Affiliate or Agent
being subject to confidentiality and non-use obligations at least as restrictive as those contained herein); or as and to the extent required by any national securities exchange on which it is listed; or to comply with the requirements of the United
States Securities and Exchange Commission and any similar organization of any other country in connection with regulatory submissions to any such agency and/or any government tax authority. In addition, the receiving Party may disclose Confidential
Information (i) to investors and potential investors and/or underwriters (and their respective attorneys and advisors) in connection with a financing transaction and/or potential and actual licensees or acquirers of assets relating to this
Agreement and/or (ii) to its legal, tax and financial advisors, provided that in each of the foregoing cases (i) and (ii) such Third Parties are bound by confidentiality and non-use obligations at least as restrictive as those
contained herein. 
 Section 7.3 Confidential Information 

This Agreement and the terms hereof shall be deemed to be Confidential Information of each of Fourteen22 and Moksha8; provided, however that
the Parties may disclose without limitation the tax treatment, tax structure and any tax advice received by such Party (and any related facts and materials) to any person. 

Section 7.4 Return of Materials. 

The Parties commit to promptly return or destroy, after the termination of this Agreement, all documents received from the other Party, which
may contain Confidential Information, as well as any copies of such documents, if any. Notwithstanding the foregoing, a receiving Party shall not be bound to effect such return, destruction or erasure, to the extent it is obliged to keep the
Confidential Information as a matter of mandatory law or pursuant to its regular data archiving and record retention policies and practices in effect as of the date hereof. 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 ARTICLE VIII  

TERM AND TERMINATION 

Section 8.1 Term. 

The term of the Agreement shall commence on the Effective Date and extend until the expiration and satisfaction of all payment obligations
hereunder, unless this Agreement is terminated earlier in accordance with this Article VIII (the “Term”). 

Section 8.2 Termination for Breach. 

The non-breaching Party may terminate this Agreement in its entirety in case of material breach of any material provision of the
present Agreement by providing written notice of said breach. If the breaching party does not cure such breach within sixty (60) calendar days after receipt of such notice (the “Cure Period”), then the non-breaching
party may terminate the Agreement in its entirety without further notice. The Cure Period shall be tolled during such time period that the Parties dispute whether there is a breach of the Agreement and the dispute has not been finally resolved
pursuant to Section 9.11. 
 Section 8.3 Consequences of Termination, Expiration 

(a) Termination by Fourteen22; Expiration. If Fourteen22 terminates the Agreement because of Moksha8’s breach, or this Agreement
expires in accordance with its terms, Fourteen22’s obligation to pay all revenue payments set forth in Section 2.1, 2.2 and 2.4 shall [***]. 

(b) Termination by Moksha8. If Moksha8 terminates the Agreement under Section 8.2 because of Fourteen22’s breach,
Moksha8’s rights of negotiation under Article III, and Fourteen22’s obligations to pay all amounts under Sections 2.1 and 2.2 shall terminate concurrently. 

Section 8.4 Survival. 

Notwithstanding Section 8.3, the following provisions shall survive expiration or early termination of this Agreement: Article VI,
Article VII, Sections 2.8 and 2.9, and Article IX. 
 ARTICLE IX 

MISCELLANEOUS 

Section 9.1 Amendment or Waiver. 

Except as expressly stated herein, neither this Agreement nor any terms hereof may be amended, waived, discharged or terminated unless such
amendment, waiver, discharge or termination is in writing signed by all of the Parties or, in the case of a waiver, by the Party waiving compliance. 

Section 9.2 Severability. 

If any one or more of the provisions contained in this Agreement shall be deemed invalid, illegal or unenforceable in any respect by a court
of competent jurisdiction, the validity, legality and enforceability of the remaining provisions contained herein shall not in any way be affected 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
or impaired. In the case of any such invalidity, illegality or unenforceability, the Parties agree to use Commercially Reasonable Efforts to achieve the purpose of such provision by a new legally
valid and enforceable stipulation. 
 Section 9.3 No Strict Construction. 

This Agreement shall be deemed prepared jointly by the Parties and shall not be construed against either Party. 

Section 9.4 Agency. 

Neither Party will be deemed to be, an employee, partner, agent or representative of the other Party for any purpose. Each Party is an
independent contractor. Neither Party shall have the authority to speak for, represent or obligate the other Party in any way without prior written consent from the other Party. 

Section 9.5 Third Party Rights. 

Nothing contained herein, express or implied, is intended or shall be construed to confer upon or give any Person, other than the Parties, any
rights or remedies under or by reason of this Agreement. 
 Section 9.6 Entire Agreement. 

This Agreement sets forth the entire understanding of the Parties relating to the subject matter thereof and supersedes all prior agreements
and understandings among or between any of the Parties relating to the subject matter thereof; provided, however, the terms of that certain Asset Transfer Agreement entered by Moksha8 and Fourteen22 effective May 14, 2009, and that certain
Assignment and Assumption Agreement entered by Moksha8, Fourteen22 and Reliance Biopharmaceuticals Private effective March 23, 2009, shall remain in effect and shall not be amended, modified or superseded by this Agreement. No license or other
rights are or shall be created or granted hereunder by implication, estoppel or otherwise. All licenses and rights are or shall be granted only as expressly provided in this Agreement. 

Section 9.7 Non-Waiver; Other Remedies. 

No failure or delay on the part of any Party in exercising any right, power or privilege hereunder and no course of dealing among the Parties
shall operate as a waiver thereof; nor shall any single or partial exercise of any right, power or privilege hereunder preclude any other or further exercise thereof or the exercise of any other right, power or privilege hereunder. The rights,
powers and remedies herein expressly provided are cumulative and not exclusive of any rights, powers or remedies which the Parties may otherwise have at law or in equity. No notice to or demand on a Party in any case shall entitle such Party to any
other or further notice or demand in similar or other circumstances or constitute a waiver of the rights of the other Party to any other or further action in any circumstances without notice or demand. 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 Section 9.8 Assignability. 

This Agreement and the rights and obligations hereunder shall not be assignable or transferable by any Party without the prior written consent
of the other Party, provided that either Party may assign its rights and obligations under this Agreement without the prior written consent of the other (a) to an Affiliate, or (b) in connection with any Change in Control transfer, sale or
other disposition of all or substantially all of its assets to which this Agreement pertains whether by operation of law, connection with a merger or sale or otherwise. If Fourteen22 assigns its ownership of any Product to a Third Party, whether in
connection with a Change of Control or otherwise, the payment obligations set forth in Sections 2.1, 2.2 and 2.3 shall remain in effect with respect to the particular Product and the assignee shall thereafter be solely responsible therefore.
Any instrument purporting to make an assignment in violation of this Section 9.8 shall be void. All covenants, agreements, representations, warranties and undertakings in this Agreement made by and on behalf of any Party shall bind and inure to
the benefit of the successors and permitted assigns of such Party. 
 Section 9.9 Costs and Expenses of the Parties. 

Each Party to this Agreement will bear its respective costs and expenses incurred in connection with the negotiation and consummation of this
Agreement and the transactions contemplated hereby (including, the fees, expenses and disbursements of its counsel). 
 Section 9.10
Governing Law. 
 This Agreement shall be construed in accordance with and be governed by the laws of the State of New York without
regard to any conflict of laws principles. The United Nations Convention on Contracts for the International Sale of Goods shall not apply to this Agreement. 

Section 9.11 Dispute Resolution. 

Any controversy or claim arising out of or relating to the present Agreement shall be finally settled by arbitration in
accordance with the American Arbitration Association (“AAA”) International Arbitration Rules in effect on the date of the commencement of the arbitral proceeding (the “Rules”) by a single arbitrator
appointed in accordance with said Rules which arbitrator shall be a former judge of a court of general jurisdiction. The arbitration shall be conducted in English and shall take place in New York, New York. The arbitration award shall be binding on
the Parties hereto and shall be enforced in any court of competent jurisdiction. Without prejudice to the validity of this arbitration clause, the Parties hereby acknowledge and agree that they may have recourse to any court of competent
jurisdiction with the sole objective and for the sole purpose of, if and when necessary, requesting measures of a provisional, precautionary or conservatory nature in aid of the arbitration either to be initiated or already in process between the
Parties and/or guarantee the existence and enforceability of the relevant arbitration proceeding, provided that once such measures are granted, the jurisdiction for any decision on the merits or of a procedural nature, which have given rise to such
measure, shall revert to the arbitrator. Each Party shall bear its own costs and expenses and an equal share of the arbitrators’ and administrative fees of arbitration. Except as may be required by law, neither a Party nor an arbitrator may
disclose the existence, content, or results of any arbitration hereunder without the prior written consent of both Parties. 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 Section 9.12 Notices. 

Any notice or other communication required or permitted to be delivered to any Party under this Agreement shall be in writing and shall be
deemed properly delivered, given and received: (a) when delivered by hand; (b) on the day sent by facsimile provided the sender has received confirmation of successful transmission as of or prior to 5:00 pm local time on a business
day at the intended recipient’s location; (c) the first business day after sent by facsimile (to the extent the sender received confirmation of successful transmission after 5:00 pm local time or on a day that is not a business day at
the intended recipient’s location); or (d) the second business day after sent by international courier service, and any notice under “(a)” through “(d)” above shall be sent to the address or facsimile number set forth
beneath the name of such party below (or to such other address or facsimile number as such Party shall have specified in a written notice given to the other Party hereto): 

If to Moksha8: 
 Moksha8
Pharmaceuticals, Inc. 
 1550 Liberty Ridge Drive, Suite 300 

Wayne, PA 19087 
 USA 

ATTN: Chief Business Officer 

With a copy to: 
 Moksha8
Pharmaceuticals, Inc. 
 1550 Liberty Ridge Drive, Suite 300 

Wayne, PA 19087 
 USA 

ATTN: Vice President, Legal 
 If
to Fourteen22: 
 Fourteen22, Inc. 

836 Alvarado Street 
 San
Francisco, CA 94114 
 Section 9.13 Headings Descriptive. 

The headings of the Articles and Sections of this Agreement are inserted for convenience only and shall not in any way affect the meaning or
construction of any provision of this Agreement. 
 Section 9.14 Counterparts. 

This Agreement may be executed in any number of counterparts and each such counterpart shall be deemed to be an original instrument, but all
such counterparts together shall constitute but one agreement. 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 Section 9.15 Force Majeure. 

Neither Party shall be liable for delay in delivery or nonperformance in whole or in part (other than a failure to pay any
amount due hereunder), nor shall the other Party have the right to terminate this Agreement except as otherwise specifically provided in this Section 9.15, where delivery or performance has been affected by a condition beyond such Party’s
reasonable control (“Force Majeure”), including fires, floods, embargoes, shortages, epidemics, quarantines, war, acts of war (whether war be declared or not), terrorism, insurrections, riots, civil commotion, strikes,
lockouts or other labor disturbances, acts of God or acts, or omissions or delays in acting by any governmental authority; provided that the Party affected by such a condition shall, within [***] of its occurrence, give notice to the other Party
stating the nature of the condition, its anticipated duration and any action being taken to avoid or minimize its effect. The suspension of performance shall be of no greater scope and no longer duration than is reasonably required and the
nonperforming Party shall use commercially reasonable efforts to remedy its inability to perform; provided, however, that in the event the suspension of performance continues for [***] after the date of the occurrence, and such failure to perform
would constitute a material breach of this Agreement in the absence of such Force Majeure event, the non-affected Party may terminate this Agreement immediately by written notice to the affected Party. 

[REMAINDER OF PAGE INTENTIONALLY BLANK] 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 IN WITNESS WHEREOF, the
Parties have caused this Revenue and Negotiation Rights Agreement to be executed as of the Effective Date. 
  

									
	Fourteen22, Inc.	 		 	Moksha8 Pharmaceuticals, Inc.
					
	By:	 	 /s/ Balkrishan “Simba” Gill
	 		 	By:	 	 /s/ Balkrishan “Simba” Gill

					
	Name:	 	 BALKRISHAN “SIMBA” GILL
	 		 	Name:	 	 BALKRISHAN “SIMBA” GILL

					
	Title:	 	 DIRECTOR
	 		 	Title:	 	 CEO

					
	Date:	 	 12/31/2010
	 		 	Date:	 	 12/31/2010

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 Appendix A 

Countries in the M8 Territory 

[***] 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00234-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00234-of-00352.parquet"}]]